Metal substrate for absorbable medical device, absorbable medical device, and preparation method

By designing the metal matrix of the core and surface in absorbable medical devices and controlling the distribution of metal elements and non-metal element compounds, the problems of insufficient mechanical and corrosion properties of existing devices are solved, achieving stable degradation in vivo and good biocompatibility.

WO2026238144A1PCT designated stage Publication Date: 2026-11-19BIOTYX MEDICAL (SHENZHEN) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/097610
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-18
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing absorbable implantable medical devices have shortcomings in terms of mechanical properties, degradation performance, and biocompatibility, especially the problem of excessively rapid corrosion rate of magnesium-based alloys and slow degradation rate of iron-based alloys, which limits their clinical application.

Method used

A metal matrix design is adopted, including a core and a surface. By controlling the type and concentration distribution of metal elements at the interface, a structure with excellent mechanical properties and early corrosion resistance is formed. The surface and the core are connected by metallic and ionic bonds, and non-metallic elements are combined to form compounds to improve corrosion resistance.

Benefits of technology

It achieves degradation curves that maintain structural integrity and mechanical properties within 1 to 6 months, while avoiding biocompatibility issues such as tissue proliferation, meeting clinical needs, and optimizes corrosion performance by controlling porosity and corrosion potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026097610_19112026_PF_FP_ABST
    Figure CN2026097610_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a metal substrate for an absorbable medical device, an absorbable medical device, and a preparation method. The metal substrate comprises a core portion and a surface portion, an interface being arranged between the surface portion and the core portion, and the surface portion wrapping the core portion along the interface. The absorbable medical device comprises a metal substrate and a degradable polymer layer covering at least a portion of the surface of the metal substrate. The metal substrate provided by the present invention has excellent mechanical properties and good corrosion resistance, can meet clinical requirements for mechanical properties and corrosion resistance of substrates, and does not introduce new biocompatibility and effectiveness problems such as tissue hyperplasia after being implanted in the body. The medical device provided by the present invention has a clinically ideal degradation curve and good biocompatibility and safety.
Need to check novelty before this filing date? Find Prior Art

Description

Metal matrix for absorbable medical devices, absorbable medical devices and their preparation methods Technical Field

[0001] This invention relates to the field of implantable medical devices, specifically to a metal matrix for absorbable medical devices, absorbable medical devices, and a method for their preparation. Background Technology

[0002] Currently, the vast majority of implantable medical devices on the market are made of non-degradable metal materials. Because metal materials are non-degradable and difficult to remove, their retention in the body can easily lead to adverse events such as late-stage thrombosis. Therefore, biodegradable implantable medical devices made from biodegradable polymers or biodegradable metal materials will become the main direction of future development.

[0003] In recent years, absorbable implantable medical devices, such as vascular stents, have been a significant innovation in the field of cardiovascular interventional therapy, avoiding the complications caused by the permanent implantation of traditional inert metal stents. However, clinical practice has placed high demands on the mechanical properties, degradation / corrosion performance, safety, and biocompatibility of absorbable implantable medical devices. Absorbable implantable medical devices not only need to possess good mechanical properties, safety, and biocompatibility, but also require an ideal degradation curve. This ensures that the absorbable implantable medical device can fully maintain structural integrity and sufficient mechanical properties during the tissue healing period at the implantation site (1–6 months). After fulfilling its intended purpose, the lesion site heals, and normal morphology and function are restored, the absorbable implantable medical device should be completely corroded or degraded and rapidly absorbed by the tissue.

[0004] Currently, the matrix materials for absorbable medical devices mainly fall into three categories: biodegradable polymers, magnesium-based alloys, and iron-based alloys. Among these, polylactic acid (PLA) is the most widely used biodegradable polymer, capable of complete degradation into CO and H₂O in vivo, exhibiting good biocompatibility. However, PLA has relatively low mechanical strength and high brittleness, making it difficult to meet the clinical requirements for mechanical performance in load-bearing implantable devices. Compared to polymer-based materials, magnesium-based alloys and iron-based alloys possess higher mechanical strength and superior processability. However, the mechanical properties and corrosion resistance of magnesium-based alloys still need improvement, and their rapid corrosion rate in physiological environments, accompanied by hydrogen gas generation, not only makes it difficult to guarantee mechanical support performance in the initial implantation stage but may also induce local inflammatory reactions, limiting their clinical application. While iron-based alloys combine superior mechanical properties and biocompatibility, and are considered important candidate materials for absorbable vascular stents, their slow in vivo degradation rate remains a key bottleneck restricting their development. Although existing studies have regulated the corrosion behavior of iron-based materials through surface modification and other means, which has improved their degradation performance to some extent, there is still room for optimization in the relevant technical solutions. Furthermore, the newly introduced substances during the modification process may bring new risks to biosafety and clinical efficacy.

[0005] Therefore, there is a need for a metal matrix that can overcome the defects of existing metal matrices in terms of corrosion performance, so that the degradation curve of the medical device prepared by it is close to the ideal degradation curve in clinical practice, without introducing new biocompatibility and safety issues. Summary of the Invention

[0006] Based on this, the present invention provides a substrate for absorbable medical devices, which possesses excellent mechanical properties and early corrosion resistance, and will not cause new biocompatibility and safety issues such as tissue hyperplasia after implantation. The metal substrate for absorbable medical devices provided by the present invention includes a core and a surface portion.

[0007] According to the metal matrix for absorbable medical devices provided by the above technical solution, an interface exists between the surface portion and the core portion. The surface portion encloses the core portion along the interface. In some embodiments of the present invention, the interface may be visible under certain detection methods; in some embodiments of the present invention, the interface may be invisible even with certain detection measures; in some embodiments of the present invention, the interface may be regular; in some embodiments of the present invention, the interface may be irregular. In some embodiments of the present invention, the concentration of at least one element will change significantly at the interface. In some embodiments of the present invention, the interface is an interface formed by several scattered points / surfaces. For example, in some examples, the surface portion is provided with several grooves, and the grooves contain blocky, strip-shaped, or granular substances different from the core portion. In this case, the interface is a curve or surface extending along the outer edge of the surface portion, formed by the bottom of two or more grooves, i.e., the point / surface of the groove furthest from the outer edge of the surface portion; in some embodiments of the present invention, the interface is an interface formed by countless points. In some embodiments of the present invention, the surface portion wraps around the core portion along the interface; in some embodiments of the present invention, the surface portion completely wraps around the core portion along the interface.

[0008] In this invention, the surface portion may differ from the core portion only in the type or content of a certain element; it may be the same as the core portion only in the type or content of a certain element; the type and content of the element in the surface portion may be completely different from the core portion; or the surface portion may be a core portion with several additional grooves filled with a substance whose type or content of the element is different from that in the core portion.

[0009] According to the metal matrix for absorbable medical devices provided by the above technical solution, the number of metal element types in the core is no more than the number of metal element types in the surface portion, thus the metal matrix can have better mechanical properties and corrosion resistance. In some embodiments, the number of metal element types in the core of the metal matrix is ​​equal to the number of metal element types in the surface portion of the metal matrix; in some embodiments, the number of metal element types in the core of the metal matrix is ​​less than the number of metal element types in the surface portion of the metal matrix.

[0010] Furthermore, the metal matrix for absorbable medical devices provided by the present invention comprises, on its surface portion, at least one elemental metal and / or metal alloy formed from at least one metallic element B selected from iron, magnesium, aluminum, calcium, sodium, copper, manganese, chromium, selenium, molybdenum, cobalt, nickel, vanadium, tin, strontium, cerium, lithium, potassium, palladium, tungsten, titanium, rhenium, gold, platinum, tantalum, germanium, bismuth, silver, gallium, niobium, hafnium, zinc, and zirconium. It can be understood that the surface portion of the metal matrix comprises at least one elemental metal and / or metal alloy formed from at least one metallic element selected from iron, magnesium, aluminum, calcium, sodium, copper, manganese, chromium, selenium, molybdenum, cobalt, nickel, vanadium, tin, strontium, cerium, lithium, potassium, palladium, tungsten, titanium, rhenium, gold, platinum, tantalum, germanium, bismuth, silver, gallium, niobium, hafnium, and zirconium. Further, the surface portion may be at least one elemental metal and / or at least one metal alloy. In some embodiments of the present invention, the surface portion of the metal substrate is elemental metal A; while in other embodiments, the surface portion of the metal substrate is metal alloy a. In some embodiments of the present invention, the surface portion of the metal substrate is a combination of elemental metal A and elemental metal B; in some embodiments, the surface portion of the metal substrate is a combination of elemental metal A and metal alloy a; in some embodiments, the surface portion of the metal substrate is a combination of metal alloy a and metal alloy b.

[0011] According to the above-described technical solution, the surface portion of the metal substrate for absorbable medical devices contains at least one metal element A identical to that in the core portion. In this invention, the presence of at least one metal element A identical to that in the core portion in the metal surface layer can improve the corrosion resistance of the metal substrate.

[0012] Furthermore, the metal element A is at least one selected from iron, magnesium, zinc, manganese, and aluminum. In some embodiments of the present invention, the metal element A can be any one of iron, magnesium, and aluminum; in some embodiments of the present invention, the metal element A can be any two of iron, magnesium, and aluminum; in some embodiments of the present invention, the metal element A can be three of iron, magnesium, and aluminum.

[0013] Furthermore, there is a significant difference in the concentration of metal element A between the surface and core of the metal matrix.

[0014] According to the metal matrix for absorbable medical devices provided by the above technical solution, the content of at least one metal element A, which is the same as the core, in the surface portion is distributed in an increasing trend from the outer edge of the surface portion to the interface, or the at least one metal element A exists only in the portion of the surface portion near the core.

[0015] According to the metal matrix for absorbable medical devices provided by the above technical solution, the content of at least one metal element A at the outer edge of the surface portion is 0, or tends to be 0. That is, the content of at least one metal element A at the outer edge of the surface portion tends to be 0, meaning its content is less than 0.001 wt.%.

[0016] According to the metal matrix for absorbable medical devices provided by the above technical solution, the content of at least one metal element B is distributed in a decreasing trend from the outer edge of the surface portion to the interface.

[0017] In some embodiments of the present invention, the outer edge of the core of the metal substrate and the interface may be the same; in some embodiments of the present invention, the outer edge of the core of the metal substrate and the interface may be different; in some embodiments of the present invention, the outer edge of the core of the metal substrate may be clear; in other embodiments of the present invention, the outer edge of the core of the metal substrate may be blurred or unclear.

[0018] According to the above-described technical solution, the surface portion of the metal substrate and the core portion are tightly bonded together to form a whole, thereby enabling them to have a certain degree of synchronicity in some physical properties. This effectively improves the corrosion resistance of the metal substrate and promotes endothelialization of the medical device prepared from the metal substrate to a certain extent. In some embodiments of the present invention, the surface portion and the core portion of the metal substrate are connected by metallic bonds and / or ionic bonds. In other embodiments, the outer edge of the core portion of the metal substrate has an uneven, gear-like structure, allowing the core portions of the metal substrate to be tightly interlocked. In still other embodiments, the surface portion and the core portion of the metal substrate are connected by both metallic bonds and / or ionic bonds, and are also physically interlocked.

[0019] In the above-described technical solution of the present invention, the outer edge of the metal substrate core has an average roughness Ra of 3 nm to 40 nm. Further, the outer edge of the metal substrate core has an average roughness Ra of 3 nm to 25 nm; further, the outer edge of the metal substrate core has an average roughness Ra of 5 nm to 20 nm; further, the outer edge of the metal substrate core has an average roughness Ra of 8 nm to 15 nm.

[0020] According to the above-described technical solution, the surface portion of the metal matrix for absorbable medical devices comprises 0.0001 wt.% to 5 wt.% of non-metallic elements. The non-metallic elements include at least one of carbon, nitrogen, oxygen, boron, sulfur, phosphorus, hydrogen, and silicon. Adding the aforementioned non-metallic elements to the surface portion of the present invention to form compounds or a second phase with the aforementioned metallic elements and dispersing them within the surface portion can improve the corrosion resistance and mechanical properties of the surface portion. In some embodiments of the present invention, the mass percentage of non-metallic elements in the surface portion is 0.0001 wt.% to 5 wt.% of the entire surface portion; in some embodiments of the present invention, the mass percentage of non-metallic elements in the surface portion is 0.0001 wt.% to 3 wt.% of the entire surface portion; in some embodiments of the present invention, the mass percentage of non-metallic elements in the surface portion is 0.001 wt.% to 3 wt.% of the entire surface portion; in some embodiments of the present invention, the mass percentage of non-metallic elements in the surface portion is 0.001 wt.% to 2.5 wt.% of the entire surface portion. In some embodiments of the present invention, the surface portion comprises non-metallic elements at a mass percentage of 0.001 wt.% to 2 wt.% of the entire surface portion; in some embodiments of the present invention, the surface portion comprises non-metallic elements at a mass percentage of 0.001 wt.% to 1 wt.% of the entire surface portion; in some embodiments of the present invention, the surface portion comprises non-metallic elements at a mass percentage of 0.001 wt.% to 1.5 wt.% of the entire surface portion; in some embodiments of the present invention, the surface portion comprises non-metallic elements at a mass percentage of 0.001 wt.% to 0.5 wt.% of the entire surface portion.

[0021] According to the above technical solution, the surface portion of the metal matrix for absorbable medical devices does not contain zinc or the zinc content in the surface portion is 0.0001 wt.% to 6 wt.%. The presence of zinc in the device is a double-edged sword. Therefore, controlling the presence of zinc in this application is beneficial to improving the biocompatibility of the metal matrix and reducing the toxic side effects on the tissues surrounding the implanted device.

[0022] This invention provides a material with excellent mechanical properties and good corrosion resistance in any environment by controlling the types, distribution, and content of elements in the core and surface. In particular, it can maintain the integrity of the structure and have sufficient mechanical properties in the body for 1 to 6 months without introducing new problems such as tissue hyperplasia.

[0023] According to the metal matrix for absorbable medical devices provided by the above technical solution, the content of at least one metal element A, which is the same as that in the core, in the surface portion is 0.0001 wt.% to 6 wt.% or 30 wt.% to 99 wt.% of the total mass of the surface portion.

[0024] According to the above technical solution, the porosity of the surface portion of the metal substrate for absorbable medical devices is no greater than 3%, and the pore diameter of the surface portion is no greater than 1000 nm. The porosity and pore diameter of the variable portion affect the corrosion resistance of the metal substrate and also affect the endothelialization rate of the medical device made from the metal substrate. This invention, by controlling the porosity and pore diameter, can effectively promote endothelialization of the device surface and also improve the overall corrosion resistance of the metal substrate. In some embodiments of this invention, the porosity of the surface portion is no greater than 2%, and the pore diameter of the surface portion is no greater than 900 nm; in some embodiments of this invention, the porosity of the surface portion is no greater than 1.5%, and the pore diameter of the surface portion is no greater than 800 nm; in some embodiments of this invention, the porosity of the surface portion is no greater than 1%, and the pore diameter of the surface portion is no greater than 700 nm.

[0025] According to the above technical solution, the core of the absorbable medical device metal matrix includes at least one of pure magnesium, magnesium alloy, pure iron, ferroalloy, pure zinc, zinc alloy, pure manganese, manganese alloy, pure aluminum, and aluminum alloy. Further, the iron content in the core is greater than 25 wt.%. Further, in this invention, the ferroalloys include, but are not limited to, iron-nitrogen alloy, iron-manganese alloy, iron-zinc alloy, iron-magnesium alloy, iron-calcium alloy, iron-zirconium alloy, iron-manganese-carbon alloy, iron-molybdenum alloy, iron-manganese-copper alloy, iron-manganese-silicon-carbon alloy, iron-silicon-manganese alloy, iron-copper alloy, iron-copper-manganese-carbon alloy, iron-gold alloy, iron-silver alloy, iron-manganese-silver alloy, iron-phosphorus alloy, iron-sulfur alloy, iron-boron alloy, iron-titanium alloy, and iron-titanium-carbon alloy.

[0026] According to the above technical solution, the metal matrix for absorbable medical devices contains 200ppm to 2000ppm of nitrogen in its core.

[0027] According to the above technical solution, the carbon content in the core of the absorbable medical device metal matrix is ​​less than or equal to 2.11 wt.%.

[0028] According to the above technical solution, the surface portion of the metal matrix for absorbable medical devices contains iron, and the iron content is 0.0001 wt.% to 3 wt.% or 30 wt.% to 99 wt.% of the total mass of the surface portion. The presence of an appropriate amount of iron in the surface portion of the metal matrix can effectively improve the overall corrosion resistance of the metal matrix. The iron content is 0.0001 wt.% to 6 wt.% or 40 wt.% to 98 wt.% of the total mass of the surface portion; in some embodiments of the present invention, the iron content is 0.001 wt.% to 2.5 wt.% or 50 wt.% to 98 wt.% of the total mass of the surface portion; in some embodiments of the present invention, the iron content is 0.001 wt.% to 1.5 wt.% of the total mass of the surface portion; in some embodiments of the present invention, the iron content is... The content of iron is 0.001 wt.% to 1.0 wt.% of the total mass of the surface portion; in some embodiments of the present invention, the content of iron is 0.001 wt.% to 0.5 wt.% of the total mass of the surface portion; in some embodiments of the present invention, the content of iron is 0.001 wt.% to 0.1 wt.% of the total mass of the surface portion; in some embodiments of the present invention, the content of iron is 0.001 wt.% to 0.05 wt.% of the total mass of the surface portion.

[0029] According to the above technical solution, the metal substrate for absorbable medical devices has a surface metal corrosion potential E. c The value is -0.15V to -2.9V. Furthermore, the metal corrosion potential E of the surface portion... c The voltage rating is [-0.15V, -0.74V] or [-0.77V, -2.9V].

[0030] According to the metal matrix for absorbable medical devices provided by the above technical solution, the absolute value of the potential / electric potential difference between the core and the surface portion is 0.05V to 2.5V. Further, the absolute value of the potential / electric potential difference between the core and the surface portion is [0.05V, 0.20V] or [0.23V, 2.5V].

[0031] The metal corrosion potential E on the surface of the metal substrate in the technical solution of this invention cThe absolute value of the potential / electric potential difference between the metal substrate core and the surface portion is a key factor affecting the corrosion resistance of the metal substrate. This invention further optimizes the early corrosion resistance and mechanical properties of the metal substrate by controlling the range of these two corrosion potentials. In specific examples, the absolute value of the potential / electric potential difference on the surface portion of the metal substrate can be, but is not limited to, 0.05V, 0.1V, 0.2V, 0.3V, 0.4V, 0.5V, 0.6V, 0.7V, 0.8V, 0.9V, 1.0V, 1.1V, 1.2V, 1.3V, 1.4V, 1.5V, 1.6V, 1.7V, 1.8V, 1.9V, 2.0V, 2.1V, 2.2V, 2.3V, 2.4V, or 2.5V. Wherein, the potential / electric potential difference between the metal substrate core and the surface portion = the potential / electric potential of the metal substrate core - the potential / electric potential of the surface portion.

[0032] According to the metal matrix for absorbable medical devices provided by the above technical solution, the total molar amount n of each element per unit area of ​​the surface portion is... c 1.00×10 -10 mol / mm 2 ~1.00×10 -6 mol / mm 2 In this invention, the total molar amount of each element per unit area of ​​the surface portion is controlled within this range. The metal substrate exhibits good overall corrosion resistance, ensuring that the core is essentially not corroded in the early stages and that medical devices prepared using this substrate can rapidly undergo endothelialization, thereby reducing the risk of thrombosis. In some embodiments of this invention, the total molar amount n of each element per unit area of ​​the surface portion... c 1.00×10 -10 mol / mm 2 ~5.00×10 -7 mol / mm 2 In some embodiments of the present invention, the total molar amount n of each element per unit area of ​​the surface portion is... c 1.00×10 -10 mol / mm 2 ~1.50×10 -7 mol / mm 2 In some embodiments of the present invention, the total molar amount n of each element per unit area of ​​the surface portion is... c 6×10 -8 mol / mm 2 ~5×10 -7 mol / mm 2 In some embodiments of the present invention, the total molar amount n of each element per unit area of ​​the surface portion is... c 6×10 -8mol / mm 2 ~1.5×10 -7 mol / mm 2 In some embodiments of the present invention, the total molar amount n of each element per unit area of ​​the surface portion is... c 6×10 -8 mol / mm 2 ~1.3×10 -7 mol / mm 2 The technical solution in this invention achieves better corrosion resistance of the metal substrate with a smaller amount of surface material, resulting in good corrosion resistance of the metal substrate under weakly acidic, neutral, and alkaline conditions. Furthermore, the reduced material usage also decreases the burden on the body, thus improving the safety of the device to a certain extent.

[0033] According to the above technical solution, the metal matrix for absorbable medical devices contains at least one of calcium, magnesium, iron, aluminum or manganese, and its content is 30 wt.% to 100 wt.% of the total mass of the surface portion.

[0034] In some embodiments of the present invention, the surface portion of the metal substrate is any one or at least two of elemental calcium, magnesium, iron, aluminum, and manganese; in other embodiments of the present invention, the surface portion of the metal substrate includes any one of calcium, magnesium, iron, aluminum, and manganese, and further includes at least one metallic element selected from copper, chromium, selenium, molybdenum, cobalt, nickel, vanadium, tin, strontium, cerium, palladium, tungsten, titanium, rhenium, gold, platinum, tantalum, germanium, bismuth, silver, gallium, niobium, hafnium, zinc, and zirconium; in still other embodiments of the present invention, the surface portion of the metal substrate includes elements of calcium, magnesium, iron, aluminum, and manganese. The metal substrate includes any one of iron, aluminum, and manganese, and also includes at least one of the non-metallic elements carbon, nitrogen, oxygen, boron, sulfur, phosphorus, hydrogen, chlorine, and silicon; in some other embodiments of the invention, the surface portion of the metal substrate includes any one of calcium, magnesium, iron, aluminum, and manganese, and also includes at least one of the metallic elements copper, chromium, selenium, molybdenum, cobalt, nickel, vanadium, tin, strontium, cerium, palladium, tungsten, titanium, rhenium, gold, platinum, tantalum, germanium, bismuth, silver, gallium, niobium, hafnium, zinc, and zirconium, and at least one of the non-metallic elements carbon, nitrogen, oxygen, boron, sulfur, phosphorus, hydrogen, chlorine, and silicon.

[0035] In some embodiments of the present invention, the surface portion of the metal substrate may be made of pure calcium, pure magnesium, pure aluminum, or pure manganese. In some embodiments of the present invention, the surface portion of the metal substrate may also include, but is not limited to, at least one of the following: calcium-magnesium alloy, calcium-magnesium-carbon alloy, calcium-aluminum alloy, calcium-zinc alloy, aluminum-copper alloy, aluminum-cobalt alloy, aluminum-chromium-carbon alloy, aluminum-manganese alloy, aluminum-nickel alloy, aluminum-iron-nitrogen alloy, aluminum-titanium alloy, aluminum-niobium alloy, aluminum-zirconium-nitrogen alloy, aluminum-titanium-boron alloy, aluminum-cobalt-silicon alloy, magnesium-zinc alloy, magnesium-zinc-nitrogen alloy, magnesium-copper alloy, magnesium-iron alloy, magnesium-cobalt alloy, magnesium-zirconium-titanium alloy, magnesium-cobalt-boron alloy, magnesium-copper-silicon alloy, magnesium-nickel-carbon alloy, iron-copper alloy layer, iron-silver alloy, iron-palladium alloy, iron-titanium alloy, iron-zirconium-niobium alloy, iron-tantalum alloy, iron-titanium-carbon alloy, iron-zirconium-nitrogen alloy, iron-cobalt-boron alloy, and iron-niobium-silicon alloy.

[0036] If the content of the aforementioned elements on the surface of the metal substrate is too low in the technical solution of this invention, metastable or heterogeneous phases may form, resulting in an unstable surface structure and affecting the overall corrosion performance of the metal substrate. Only when the content of the aforementioned elements on the surface of the metal substrate is within a specific range can a good synergistic corrosion resistance effect be achieved, thereby ensuring good corrosion resistance of the metal substrate in the early stages. The content of the aforementioned elements on the surface of the metal substrate provided by this invention can form a stable and uniform surface, producing a uniform and continuous corrosion process, thereby achieving slight corrosion or no corrosion in the early stages. In some embodiments of this invention, the content of the aforementioned elements on the surface of the metal substrate is greater than or equal to 30 wt.% and less than or equal to 100 wt.%; in some embodiments of this invention, the content of the aforementioned elements on the surface of the metal substrate is greater than or equal to 50 wt.% and less than or equal to 100 wt.%; in some embodiments of this invention, the content of the aforementioned elements on the surface of the metal substrate is greater than or equal to 60 wt.% and less than or equal to 100 wt.%. In some embodiments of the present invention, the content of the aforementioned elements in the surface portion of the metal substrate is greater than or equal to 70 wt.% and less than or equal to 100 wt.%; in some embodiments of the present invention, the content of the aforementioned elements in the surface portion of the metal substrate is greater than or equal to 80 wt.% and less than or equal to 100 wt.%; in other embodiments of the present invention, the content of the aforementioned elements in the surface portion of the metal substrate is greater than or equal to 90 wt.% and less than or equal to 100 wt.%. Further, the content of the aforementioned elements in the surface portion of the metal substrate is 65 wt.%-100 wt.% or 75 wt.%-100 wt.%; even further, the content of the aforementioned elements in the surface portion of the metal substrate is 85 wt.%-100 wt.% or 95 wt.%-100 wt.%. In other embodiments of the present invention, the content of the aforementioned elements on the surface of the metal substrate is 30 wt.%, 33 wt.%, 40 wt.%, 50 wt.%, 55 wt.%, 60 wt.%, 65 wt.%, 80 wt.%, 95 wt.%, 98 wt.%, or 100 wt.%.

[0037] Another aspect of the technical solution of the present invention provides an absorbable medical device, comprising the aforementioned metal substrate and a biodegradable polymer layer covering at least a portion of the surface of the metal substrate. The absorbable medical device provided by the present invention not only meets clinical requirements for the structural integrity and mechanical properties of implanted devices in the early stage (i.e., the recovery period), but also degrades rapidly after 1 to 6 months, and does not introduce new biocompatibility issues such as tissue hyperplasia after implantation. It satisfies both the clinical requirements for mechanical performance in the early stage of device implantation and the requirements for device safety, effectiveness, and corrosion resistance.

[0038] According to the absorbable medical device provided by the above technical solution, the metal corrosion potential E on the surface of the metal substrate is... c The total molar amount of each element per unit area of ​​the surface part, n c The number-average molecular weight M of the degradable polymers in the degradable polymer layer p The size of the values ​​satisfies the following relationship:

[0039] Where E c The unit is V, n c The unit is mol / mm 2 M p The unit is Da.

[0040] If The value range of S in this invention can be further narrowed to 0.2–51, 0.4–51, 0.4–40, 0.4–30, and 0.6–30, using the letter S instead.

[0041] The metal corrosion potential E of the metal substrate surface of the absorbable medical device of the present invention c The total molar amount of each element per unit area of ​​the surface part, n c The number-average molecular weight M of the degradable polymers in the degradable polymer layer p The magnitude of these parameters collectively affects the corrosion rate of the iron-based matrix. Extensive experiments have demonstrated that when the above parameters satisfy the aforementioned relationship, absorbable medical devices can achieve a relatively ideal corrosion / degradation curve.

[0042] According to the absorbable medical device provided by the above technical solution, the surface portion further includes a chemical modification layer attached to its surface; the chemical modification layer includes at least one of the following functional groups: hydroxyl group, ether bond, aldehyde group, carbonyl group, carboxyl group, ester group, amide group, amino group, nitro group, sulfonic acid group, mercapto group, olefin double bond, alkyne triple bond, halogen atom or azo functional group.

[0043] According to the absorbable medical device provided by the above technical solution, the biodegradable polymer layer comprises a biodegradable polymer. Further, the total thickness of the biodegradable polymer layer is 5–30 μm. Further, the number-average molecular weight of the biodegradable polymer is 8 × 10⁻⁶. 4 Da~6×10 5 Furthermore, the pKa of the biodegradable polymer is 3.0 to 8.0. In some embodiments of the present invention, the number-average molecular weight of the biodegradable polymer is 5 × 10⁻⁶. 3 Da~1×10 6 In some embodiments of the present invention, the number-average molecular weight of the biodegradable polymer is 8 × 10⁻⁶. 4 Da~5×10 5In other embodiments, the number-average molecular weight of the degradable polymer is 1 × 10⁻⁶. 5 Da~4×10 5 Da.

[0044] According to the absorbable medical device provided by the above technical solution, the degradable polymer includes at least one of chitosan, degradable polyester, degradable polyanhydride, degradable polyamino acid, or a binary or multi-component degradable copolymer formed by copolymerizing monomers corresponding to degradable polyester, degradable polyanhydride, and degradable polyamino acid; the degradable polyester includes at least one of polylactic acid, polyglycolic acid, polylactic-glycolic acid copolymer, lactide-caprolactone copolymer, polylactic-glycolic acid, polycaprolactone, polyhydroxy fatty acid ester, polyacrylate, polysuccinate, polysalicylic anhydride ester, polytrimethylene carbonate, polydioxane, poly(β-alkanoate), poly(β-hydroxybutyrate), polyethylene glycol ester, polyethylene adipate, or polyhydroxybutyrate valerate.

[0045] The biodegradable polyanhydride includes at least one of poly(1,3-bis(p-carboxyphenoxy)propane-sebacic acid, polyurethane dimer-sebacic acid, or polyfumaric acid-sebacic acid.

[0046] The biodegradable polyamino acids include at least one of polyglycine, polyalanine, polyvaline, polyleucine, polyisoleucine, polymethionine, polyproline, polytryptophan, polyserine, polytyrosine, polycysteine, polyphenylalanine, polyasparagine, polyglutamine, polythreonine, polyarginine, polyhistidine, polyselenocysteine, polypyrrolidone, polyglutamic acid, polyaspartic acid, polyornithine, polylysine, and their derivatives.

[0047] According to the absorbable medical device provided by the above technical solution, the biodegradable polymer layer includes an active drug; the active drug includes at least one of angiogenesis inhibitors, antiplatelet drugs, antithrombotic drugs, anti-inflammatory drugs, or anti-sensitizing drugs;

[0048] The anti-angiogenic drugs include at least one of paclitaxel, rapamycin, and their derivatives; the antiplatelet drugs include at least one of cilostazol, aspirin, clopidogrel, ticagrelor, tirofiban, or dipyridamole; the antithrombotic drugs include at least one of heparin, low molecular weight heparin, fondaparinux, or argatroban; the anti-inflammatory drugs include at least one of dexamethasone, prednisone, ibuprofen, methotrexate, or levofloxacin; and the anti-sensitization drugs include at least one of calcium gluconate, loratadine, fexofenadine, ebastine, mizolastine, chlorpheniramine, diphenhydramine, triamcinolone, promethazine, levocetirizine, cortisone, hydrocortisone, or methylprednisolone.

[0049] According to the above technical solution, the absorbable medical device is an implantable medical device; the implantable medical device includes a lumen stent, an occluder, a gasket, an artificial blood vessel, a vascular clamp, a suture, a dental implant, an orthopedic implant, a gynecological implant, a urological implant, or a respiratory implant.

[0050] The luminal stents include vascular stents, airway stents, esophageal stents, biliary stents, intestinal stents, urethral stents, nerve stents, or pancreatic stents.

[0051] The vascular stents include heart valve stents, coronary stents, pulmonary artery stents, renal artery stents, vertebral artery stents, covered stents, or peripheral stents.

[0052] The orthopedic implants include bone screws, bone plates, joints, rivets, anchors, bolts, intramedullary nails, or interbody fusion devices.

[0053] The present invention also provides a method for preparing an absorbable implantable medical device, comprising: 1) forming a surface portion on the core surface to form a metal substrate for the medical device; 2) forming a degradable polymer layer on the surface of the metal substrate.

[0054] According to the method for preparing an absorbable medical device provided by the above technical solution, the surface portion in step 1) is formed by at least one of ion implantation, physical vapor deposition, or electrodeposition; before step 1), an ion etching step is also included;

[0055] The ion etching is performed in a vacuum environment at 25°C to 420°C using Ar. + Ion etching for 5 to 100 minutes.

[0056] According to the preparation method of the absorbable medical device provided by the above technical solution, the ion implantation beam current is 0.1-10mA, the bias voltage is 10kV-90kV, and the implantation dose is 1×10⁻⁶. 11 ~9×10 16 ions / cm2, time is 20-120min;

[0057] The physical vapor deposition method includes magnetron sputtering or vacuum evaporation.

[0058] The magnetron sputtering ion source voltage is 0.5kV to 3.0kV, the bias voltage is 5V to 600V, the heating temperature is 25℃ to 420℃, the sputtering power is 1.0kV to 10kW, and the time is 20min to 240min; the gaseous ions include argon ions;

[0059] The power of the vacuum evaporation method is 0.2kV to 5kW, the target distance is 15cm to 45cm, and the time is 40min to 360min; after evaporation, inert gas protection heat treatment is performed at a temperature of 150℃ to 450℃ for a time of 10min to 60min.

[0060] The electrodeposition includes constant voltage electrodeposition, constant current electrodeposition, or pulse electrodeposition; the voltage for constant voltage electrodeposition is 2V to 50V, and the current density for constant current electrodeposition is 0.01A / cm². 2 ~3.0A / cm 2 The current density for pulse electrodeposition is 0.01 A / cm. 2 ~3.0A / cm 2 The electrodeposition temperature is 10–80°C, and the pH value of the electrodeposition electrolyte is 2.0–9.0.

[0061] According to the preparation method of the absorbable medical device provided by the above technical solution, before step 2), a step of heat treatment and / or surface modification of the metal substrate is included; the temperature of the heat treatment is 100℃~420℃; the time is 10min~60min;

[0062] The surface modification involves acidifying, alkalizing, or salinizing the metal substrate to form the chemical modification layer on the surface portion.

[0063] The concentration of acid used in the acidification treatment is 0.5 wt.% to 5 wt.%, and the treatment time is 10 s to 5 min;

[0064] The concentration of alkali used in the alkalization treatment is 2 wt.% to 10 wt.%, and the treatment time is 0.5 min to 5 min;

[0065] The salt concentration used in the salinization treatment is 5 wt.% to 20 wt.%, and the treatment time is 1 min to 10 min.

[0066] It should be noted that the term "a certain alloy" in this invention refers to an alloy formed by mixing and melting a certain metal with other metals and / or non-metals. The types, quantities, and contents of the other metallic or non-metallic elements are not limited. For example, ferroalloys, as described in this invention, refer to alloys formed by mixing and melting iron metal with other metallic or non-metallic elements, where the mass / volume content of iron in the ferroalloy is greater than or equal to 0.25%. Further, the ferroalloys in this application include, but are not limited to, iron-nitrogen alloys, iron-manganese alloys, iron-zinc alloys, iron-magnesium alloys, iron-calcium alloys, iron-zirconium alloys, iron-manganese-carbon alloys, iron-molybdenum alloys, iron-manganese-copper alloys, iron-manganese-silicon-carbon alloys, iron-silicon-manganese alloys, iron-copper alloys, iron-copper-manganese-carbon alloys, iron-gold alloys, iron-silver alloys, iron-manganese-silver alloys, iron-phosphorus alloys, iron-sulfur alloys, iron-boron alloys, iron-titanium alloys, and iron-titanium-carbon alloys. Furthermore, the iron content in ferroalloys can be ≥60%, ≥70%, ≥80%, ≥90%, and even further, ≥95wt.% or ≥99wt.%.

[0067] In this invention, "pure metal" refers to a metal in which the total content of other impurities is less than or equal to 0.5 wt.%. For example, pure iron refers to a metal in which the total content of other metals and / or non-metals besides iron is less than or equal to 0.5 wt.%. In some embodiments, the carbon content of the ferroalloy is not higher than 2.11 wt.%. In some embodiments, the nitrogen content in nitrided iron is 0.02 to 0.2 wt.%.

[0068] Unless otherwise specified, the term "coating thickness" in this invention refers to the average thickness of the coating.

[0069] In this invention, "luminal stenosis" refers to the phenomenon that after an instrument is implanted in the human body, the volume of the cavity is gradually filled by proliferating cells, resulting in a gradual decrease in the inner diameter of the cavity.

[0070] It should be noted that in this invention, "A / B" represents A or B, and "A and / or B" represents A and B, or A or B. For example, "mass percentage content / mass percentage" represents mass percentage content or mass percentage; another example is "potential / potential difference" which represents potential difference or electric potential difference, and so on.

[0071] It should be noted that the biodegradable polymer layer can be one or more layers. When it is multi-layered, the number-average molecular weight of the biodegradable polymer in the above formula is the average of the number-average molecular weights of the multi-layered biodegradable polymers.

[0072] The beneficial effects of this invention are:

[0073] This invention, on the one hand, by optimizing the elemental composition, distribution, and content of the core and surface portions of the metal matrix, and by forming a tightly integrated core and surface portion, ensures that the core and surface portion exhibit synchronized behavior during a series of implantation procedures. This provides a metal matrix with excellent mechanical and corrosion resistance while ensuring good biocompatibility and efficacy, thus fully meeting the clinical requirements for the mechanical properties, corrosion resistance, biocompatibility, and efficacy of the prepared absorbable medical devices. Furthermore, the optimized combination of elemental composition, distribution, and content reduces material usage while achieving excellent corrosion resistance, thereby minimizing the burden on the body.

[0074] In another aspect, by controlling the surface potential, the molar amount per unit area of ​​the surface elements, and the molecular weight of the polymer in the polymer coating within a certain range, a medical device with a curve close to an ideal can be provided, thereby overcoming the shortcomings of metal devices in terms of corrosion performance and providing a more ideal absorbable medical device.

[0075] The absorbable medical device provided by this invention can meet the clinical requirements of non-corrosion or slight corrosion (less than or equal to 18% before the full recovery period) in the early stage of implantation, and can also degrade rapidly after recovery. Furthermore, it does not introduce new biocompatibility issues such as tissue hyperplasia after implantation. It can meet the clinical requirements for mechanical performance in the early stage of device implantation, as well as the requirements for device safety, effectiveness, and corrosivity. Attached Figure Description

[0076] Figure 1 is a schematic diagram of the absorbable medical device of Example 1, wherein 1 is the metal matrix core, 11 is the interface between the surface part and the core, 2 is the metal matrix surface part, and 3 is the biodegradable polymer layer.

[0077] Figure 2 shows an OCT image of a dog's coronary artery 3 months after the absorbable medical device of Example 1 was implanted.

[0078] Figure 3 shows an OCT image of a dog's coronary artery 3 months after the absorbable medical device of Example 18 was implanted.

[0079] Figure 4 shows an OCT image of the absorbable medical device implanted in the canine coronary artery three months after Comparative Example 3. Detailed Implementation

[0080] To make the above-mentioned objects, features, and advantages of the present invention more apparent and understandable, specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings. Many specific details are set forth in the following description to provide a thorough understanding of the present invention. However, the present invention can be practiced in many other ways different from those described herein, and those skilled in the art can make similar modifications without departing from the spirit of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0081] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

[0082] Test methods

[0083] 1. Coating thickness testing method:

[0084] The coating thickness was measured using scanning electron microscopy. First, the instrument was embedded and fixed in resin, and then a cross-section was cut along the axial direction. The thickness of the coating was observed using a scanning electron microscope on this section.

[0085] 2. Method for detecting average roughness Ra:

[0086] The average roughness Ra is defined as the average of the absolute deviations of all points on the surface from the average height. This invention uses an optical measuring device and refers to the ISO 25178 standard to measure the average roughness Ra of the outer edge of a ferrous substrate surface. For example, using an atomic force microscope (AFM), the measurement steps are as follows: the silicon probe has an elastic constant of 0.4 N / m and a resonant frequency of 70 kHz. The silicon wafer surface is scanned in ScanAsyst mode to obtain three-dimensional topographic data of a 5 × 5 μm region. Second-order plane fitting is performed using software to remove substrate tilt. A Gaussian low-pass filter (cutoff wavelength 1 μm) is applied to eliminate high-frequency noise. A central 3 × 3 μm region is selected, and the average roughness Ra is obtained through software fitting.

[0087] 3. Methods for determining the number-average molecular weight of polymers:

[0088] The number-average molecular weight of the polymers was determined using a molecular weight analysis system coupled with a multi-angle laser light scattering (MLS) instrument from Wyatt Pharmaceuticals, USA. This system included a liquid phase pump and injector from Agilent Technologies, USA; an Agilent PLMIXED-C GPC column (7.5 × 300 mm, 5 μm) from Agilent Technologies, USA; and a multi-angle laser light scattering instrument and differential detector from Wyatt Pharmaceuticals, USA. The detection conditions were: mobile phase: tetrahydrofuran; pump flow rate: 1 mL / min; injection volume: 100 μL; laser wavelength: 663.9 nm; test temperature: 35 °C.

[0089] 4. Methods for detecting weight loss in stents:

[0090] After removing the scaffold from the animal, it is washed in pure water and then in alcohol. The tissue covering the scaffold is removed with tweezers. The surface tissue is observed under a microscope to see if it has been completely removed. The scaffold is then placed in 100ml of 8% tartaric acid and sonicated for 20 minutes to remove rust from the surface. It is then rinsed 2-3 times with purified water and then rinsed 2-3 times with anhydrous ethanol. After drying, it is weighed as M1.

[0091] The formula for calculating the percentage of weight loss P in the stent is: P = (M0 - M1) / M0

[0092] in,

[0093] M0: Original bare iron-based scaffold mass / mg;

[0094] M1: Remaining iron-based mass after corrosion / mg.

[0095] 5. Methods for detecting stenosis rate:

[0096] Vascular stents were implanted into the blood vessels of experimental animals, and the vascular lumen area was measured using optical coherence tomography (OCT) at time zero and follow-up time points.

[0097] Stenosis rate = (Lumen area at time zero - Lumen area at follow-up) / Lumen area at time zero × 100%.

[0098] 6. Methods for detecting porosity and pore diameter:

[0099] In this invention, the porosity, maximum pore diameter, and average pore diameter are all obtained by measuring a mercury porosimeter.

[0100] 7. Surface potential and potential / potential difference detection method between the surface and the core.

[0101] This invention utilizes the scanning Kelvin probe method to measure material potential / potential difference, and the measurement steps are as follows:

[0102] After mounting and polishing, the samples were immersed in physiological saline for 8 hours, cleaned, and dried. The potential at the interface between the surface and core was measured using a scanning Kelvin probe method. A 100-micron probe was used for surface scanning centered on the interface, with a scanning range of 500*500 microns, a probe height of 20 microns, and a vibration amplitude of 30 microns. The potential / potential difference was calculated based on the Kelvin potentiogram. The potential / potential measured by the scanning Kelvin probe method is the surface potential / potential, i.e., the potential / potential difference is the surface potential / potential difference.

[0103] 8. The total molar amount of each element per unit area of ​​the surface part, n c

[0104] M t M0 and S0 represent the mass of the core after plating the surface area and before plating, respectively, and S is the surface area of ​​the core. a M b Let C be the atomic weights of elements a and b in the surface layer, respectively. a C b These are the mass fractions of elements a and b in the surface layer, respectively.

[0105] 9. Content of element A in the surface portion

[0106] A corrosion solution is prepared based on the material properties. This solution is highly corrosive to the surface but has little or no corrosive effect on the substrate. The sample is immersed in this corrosion solution and subjected to ultrasonic treatment. Heating may be performed simultaneously if necessary. The sample is weighed using a balance before immersion, and the weight is recorded as M0. After the surface is completely dissolved and the core is exposed, the sample is ultrasonically cleaned sequentially with distilled water and anhydrous ethanol. After complete drying, the sample is weighed again and recorded as M. 1;

[0107] The metal layer was removed using the selective etching and stripping method described above, and the etched solution was collected. The etched solution was then digested with dilute nitric acid, diluted, and brought to a final volume of 10 ml. A series of solutions (0.1 ppm to 20 ppm) with gradient concentrations of the same element (iron) were prepared, each in 10 ml volume. Inductively coupled plasma mass spectrometry (ICP-MS) was used to test the standard solutions and fit a standard curve. The test solution was then analyzed using ICP-MS. The result, C, representing the concentration of element A in the test solution, was multiplied by the final volume to obtain the total mass M of element A in the surface portion. A .

[0108] The content of element A in the surface part is M. A / (M0-M1)*100%.

[0109] 10. Surface metal element B content and non-metal element content

[0110] The method for testing the content of metal element B in the surface portion is the same as the method for testing the content of element A, i.e., the method described above (the content of element A in the surface portion). The mass M of metal element B is obtained by ICP-MS testing. B Its content is M B / (M0-M1)*100%. The content of non-metallic elements is (M0-M1-M). A -M B ) / (M0-M1)*100%.

[0111] Example 1

[0112] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0113] The iron-based core is a nitrided iron core with a nitrogen content of 0.15 wt.% and a carbon content not exceeding 2.11 wt.%. The average surface roughness Ra of the iron-based core is 30 nm. The surface completely covers the surface of the iron-based core, and the iron-based core and the surface are bonded by metallic bonds. The interface is an iron-magnesium-strontium alloy layer, and the potential difference between the iron-based core and the surface is 2.1 V. The surface contains a magnesium-strontium alloy with a magnesium content of 60% of the total mass of the surface, and also contains iron with a content of 0.002 wt.%. The metal corrosion potential Ec of the surface is -2.6 V. The total molar amount n of each element per unit area of ​​the surface is... c 1.4×10 -7 mol / mm 2 The surface portion has a porosity of 2% and a pore diameter not exceeding 800 nm, and contains carboxyl groups. A biodegradable polymer layer partially covers the surface portion (covering 90%) and is bonded to it via hydrogen bonds. The biodegradable polymer layer consists of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA, with a total thickness of 15 μm. The number-average molecular weight of the PLA is 3 × 10⁻⁶. 5 The mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0114] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0115] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the temperature was raised to 150°C and argon ion etching was performed for 60 minutes, so that the average surface roughness Ra of the iron-based core was 30 nm.

[0116] A magnesium-strontium alloy layer was formed on the surface of the etched iron-based core by magnetron sputtering. The parameters of the magnetron sputtering method were: ion source voltage of 2.0 kV, bias voltage of 60 V, heating temperature of 150 °C, sputtering power of 4 kW, and time of 120 min.

[0117] The iron-based core containing the magnesium-strontium alloy layer was heat-treated at 400℃ for 60 min; the surface of the heat-treated magnesium-strontium alloy layer was treated with 2wt.% acetic acid for 5 min to obtain the metal matrix.

[0118] A 15 μm thick biodegradable polymer layer was sprayed onto the surface of the metal substrate to obtain a scaffold. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid. The number average molecular weight of the polylactic acid was 3 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0119] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 15% was measured, and an OCT measurement showed a vascular stenosis rate of 15%. After 12 months, the stent weight loss rate was 58%.

[0120] Example 2

[0121] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0122] The iron-based core is nitrided iron with a nitrogen content of 0.04 wt.% and a carbon content not exceeding 2.11 wt.%. The average surface roughness Ra of the iron-based core is 5 nm. The surface completely encapsulates the surface of the iron-based core, and the iron-based core and the surface are bonded by metallic bonds. The interface is an iron-manganese-copper-carbon alloy layer, and the potential difference between the iron-based core and the surface is 0.1 V. The surface contains manganese with a manganese content of 30 wt.% and a carbon content not exceeding 0.5 wt.%, and also contains iron with a content of 0.01 wt%. The metal corrosion potential Ec of the surface is -0.5 V. The total molar amount n of each element per unit area of ​​the surface is... c 4.5×10 -8 mol / mm 2 The porosity is 5%, and the pore diameter is no greater than 950 nm. The surface contains amino groups. The biodegradable polymer layer partially covers the surface (covering 95% of the surface) and is bonded to the surface by hydrogen bonds. The biodegradable polymer layer consists of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with a total thickness of 10 μm. The number average molecular weight of the polylactic acid is 2 × 10⁻⁶. 5 In the sirolimus-polylactic acid coating, the mass ratio of sirolimus to polylactic acid is 12:16.

[0123] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0124] The iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was simultaneously raised to 300°C. The iron-based core was etched with argon ions for 10 minutes, and the average surface roughness Ra of the iron-based core was 5 nm.

[0125] A manganese-copper-carbon alloy layer was formed on the surface of the etched iron-based core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 0.6 kV, bias voltage of 450 V, heating temperature of 300 °C, sputtering power of 3.5 kW, and time of 100 min.

[0126] The iron-based core containing the manganese-copper-carbon alloy layer was heat-treated at 400℃ for 30 min; the surface of the heat-treated manganese-copper-carbon alloy layer was treated with 15wt.% ammonia water for 20 min.

[0127] A scaffold was prepared by spraying a 10 μm thick biodegradable polymer layer onto its surface. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid. The number average molecular weight of the polylactic acid was 2 × 10⁻⁶. 5 The mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 12:16.

[0128] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 10% was measured, and an OCT measurement showed a vascular stenosis rate of 14%. At 12 months, the stent weight loss rate was 55%.

[0129] Example 3

[0130] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0131] The metal matrix includes a magnesium-aluminum alloy core and a surface portion.

[0132] The average surface roughness Ra of the magnesium-aluminum alloy core is 28 nm; the surface completely encapsulates the magnesium-aluminum alloy core, and the core and surface are bonded by metallic bonds. The interface is a magnesium-aluminum-iron-silicon alloy layer, and the potential difference between the core and surface is 0.7 V; the surface contains an aluminum-iron-silicon alloy with an iron content of 15 wt.% and a silicon content of less than 5 wt.%; the metal corrosion potential Ec of the surface is -0.6 V, and the total molar amount n of each element per unit area of ​​the surface is... c 1×10 -6 mol / mm 2 The surface portion has a porosity of 3%, with pore diameters not exceeding 300 nm, and contains amino groups. A biodegradable polymer layer completely covers the surface portion and is bonded to it via hydrogen bonds. This biodegradable polymer layer consists of sirolimus-chitosan and chitosan, with a thickness of 5 μm. The chitosan has a number-average molecular weight of 1 × 10⁻⁶. 6 The mass ratio of sirolimus to chitosan in the sirolimus-chitosan coating is 10:16.

[0133] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0134] The magnesium-aluminum core was installed in the vacuum chamber of the equipment. After evacuation, the temperature was simultaneously raised to 100°C. The magnesium-aluminum core was etched with argon ions for 55 minutes, resulting in an average surface roughness Ra of 28 nm.

[0135] An aluminum-iron-silicon alloy layer was formed on the surface of the etched magnesium-aluminum core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 1.2kV, bias voltage of 80V, heating temperature of 100℃, sputtering power of 1kW, and time of 120min.

[0136] The magnesium-aluminum alloy core containing the aluminum-iron-silicon alloy layer was heat-treated at 300℃ for 30 minutes; the surface of the heat-treated aluminum-iron-silicon alloy layer was treated with 10wt.% ammonia water for 5 minutes to make the surface of the aluminum-iron-silicon alloy layer contain amino groups, thus obtaining the metal matrix.

[0137] A scaffold was prepared by spraying a 5 μm thick biodegradable polymer layer onto the entire surface of a metal substrate; the biodegradable polymer layer consisted of sirolimus and chitosan, with the number-average molecular weight of chitosan being 1 × 10⁻⁶. 6 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-chitosan coating is 10:16.

[0138] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 8% was measured, and an OCT measurement showed a vascular stenosis rate of 25%. After 12 months, the stent corrosion weight loss rate was 65%.

[0139] Example 4

[0140] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0141] The metal matrix includes an iron-manganese alloy core and a surface portion with a carbon content of no more than 2.11 wt.% and an iron content of 50 wt.%.

[0142] The iron-based core has a roughness of 20 nm, and the surface completely encapsulates the iron-based core. The potential difference between the iron-based core and the surface is 0.4 V. The surface comprises an iron-chromium-oxygen alloy with an iron content of 90 wt.% and oxygen content of less than 0.05 wt.%. The metal corrosion potential Ec of the surface is -0.5 V, and the total molar amount n of each element per unit area of ​​the surface is... c For 1×10 -10 mol / mm 2The surface has an average roughness Ra of 15 nm, a porosity of 0.2%, and pore diameters not exceeding 15 nm. A biodegradable polymer layer completely covers the surface; this layer consists of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA, with a total thickness of 25 μm; the number-average molecular weight of PLA is 1 × 10⁻⁶. 4 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 6:16.

[0143] The method for preparing the iron-based vascular stent in this embodiment includes the following steps:

[0144] The iron-based core was placed into the vacuum chamber of the equipment. After evacuation, the temperature was simultaneously raised to 220°C. The iron-based core was etched with argon ions for 6 minutes, so that the average surface roughness Ra of the iron-based core was 20 nm.

[0145] A ferrochromium oxide alloy layer was prepared on the surface of the iron-based core by electrodeposition to obtain the metal substrate. The parameters for the electrodeposition method were as follows: the electrolyte composition was CrCl2·6H2O (0.35 mol / L), FeCl2·4H2O (0.05 mol / L), glycine (0.35 mol / L), ammonium chloride (0.2 mol / L), and boric acid (0.2 mol / L), with a pH of 2.5. An electrolytic capacitor was used as the anode, and the electrodeposition was performed using a constant current method with a current density of 0.02 A / cm². 2 Deposition time: 30 min;

[0146] A scaffold was prepared by spraying a 25 μm thick biodegradable polymer layer onto the entire surface of a metal substrate. The biodegradable polymer layer consisted of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA. The number-average molecular weight of the PLA was 1 × 10⁻⁶. 4 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 6:16.

[0147] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 28% was measured, and an OCT measurement showed a vascular stenosis rate of 25%. After 12 months, the stent weight loss rate was 51%.

[0148] Example 5

[0149] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0150] The metal matrix includes an iron-copper alloy core with a carbon content of no more than 2.11 wt.% and an iron content of 70 wt.%, as well as a surface portion.

[0151] The average surface roughness Ra of the iron-copper alloy core is 10 nm. The surface completely encapsulates the iron-based core, and the iron-based core and surface are bonded by metallic bonds. The interface is an iron-aluminum-nitrogen alloy layer, and the potential difference between the iron-based core and the surface is 0.4 V. The surface is an iron-aluminum-nitrogen alloy layer with an iron content of 70 wt.% and a nitrogen content of less than 0.2 wt.%, with a corrosion potential Ec of -0.8 V. The total molar amount n of each element per unit area of ​​the surface is... c It is 6.3×10 -8 mol / mm 2 The porosity is 0.1%, with pore diameters not exceeding 10 nm. The surface portion contains hydroxyl groups. A biodegradable polymer layer completely covers the surface portion and is bonded to it via hydrogen bonds. The biodegradable polymer layer consists of three layers: polyfumaric acid-co-sebacic acid, sirolimus-polyfumaric acid-co-sebacic acid, and polyfumaric acid-co-sebacic acid. The total thickness of the biodegradable polymer layer is 30 μm, wherein the number-average molecular weight of the polyfumaric acid-co-sebacic acid is 1.5 × 10⁻⁶. 5 The mass ratio of sirolimus to polyfumaric acid (CO) sebacic acid in the sirolimus-polyfumaric acid (CO) sebacic acid coating is 10:16.

[0152] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0153] The iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was simultaneously raised to 300°C. The iron-based core was etched with argon ions for 20 minutes, and the average surface roughness Ra of the iron-based core was 10 nm.

[0154] The etched iron-based core surface was then sputtered to form an iron-aluminum-nitrogen alloy layer. The parameters for the magnetron sputtering method were: ion source voltage of 1.0 kV, bias voltage of 600 V, heating temperature of 300 °C, sputtering power of 10 kW, and time of 100 min.

[0155] The iron-based core containing the iron-aluminum-nitrogen alloy layer was heat-treated at 380°C for 30 min; the heat-treated iron-aluminum-nitrogen surface was treated with 10 wt.% potassium hydroxide for 10 min to make the iron-aluminum-nitrogen surface contain hydroxyl groups, thus obtaining a metal matrix.

[0156] A scaffold was prepared by spraying a 30 μm thick biodegradable polymer layer onto the entire surface of a metal substrate. The biodegradable polymer layer consisted of three layers: polyfumaric acid-co-sebacic acid, sirolimus-polyfumaric acid-co-sebacic acid, and polyfumaric acid-co-sebacic acid. The number-average molecular weight of the polylactic acid was 1.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0157] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 12% was measured, and an OCT measurement showed a vascular stenosis rate of 12%. After 12 months, the stent weight loss rate was 60%.

[0158] Example 6

[0159] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0160] The metal matrix includes an iron-molybdenum alloy core with a carbon content of no more than 2.11 wt.% and an iron content of 90 wt.%, as well as a surface portion.

[0161] The iron-molybdenum alloy core has an average surface roughness Ra of 3 nm; the surface portion covers 95% of the entire surface of the iron-based core; the potential difference between the iron-molybdenum alloy core and the surface portion is 0.6 V; the surface portion contains manganese and iron, with an iron content of 3 wt.% and a corrosion potential of -0.8 V; the total molar amount n of each element per unit area of ​​the surface portion is... c 3.9×10 -7 mol / mm 2 The porosity is 0.6%, and the pore diameter is no greater than 15 nm. The biodegradable polymer layer completely covers the surface portion and is bonded to the surface portion by hydrogen bonds; the biodegradable polymer layer is composed of sirolimus-polylactic acid, and the thickness of the biodegradable polymer layer is 20 μm, wherein the number average molecular weight of polylactic acid is 2 × 10⁻⁶. 5 The mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0162] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0163] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the temperature was simultaneously raised to 410°C. The iron-based core was etched with argon ions for 2 minutes. The average surface roughness Ra of the iron-based core was 3 nm.

[0164] The etched iron-based core was sputtered to form a pure manganese layer. The parameters of the magnetron sputtering method were: ion source voltage of 2.2kV, bias voltage of 150V, heating temperature of 410℃, sputtering power of 3kW, and time of 120min, to obtain a metal substrate.

[0165] A scaffold was prepared by spraying a 20 μm thick biodegradable polymer layer onto the entire surface of a metal substrate. The biodegradable polymer layer consisted of sirolimus-polylactic acid (PLA), with both PLAs having a number-average molecular weight of 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0166] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 13% was measured, and an OCT measurement showed a vascular stenosis rate of 16%. After 12 months, the stent weight loss rate was 60%.

[0167] Example 7

[0168] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0169] The metal matrix includes a nitrided iron-based core and a surface portion with a nitrogen content of 0.1 wt.% and a carbon content of no more than 2.11 wt.%.

[0170] The iron-based core has an average surface roughness Ra of 8 nm; the surface completely encloses the iron-based core, and the potential difference between the nitrided iron-based core and the surface is 1.1 V; the surface comprises a magnesium-cerium alloy with a magnesium content of 50%, contains no iron, has a corrosion potential Ec of -1.5 V, and the total molar amount of each element per unit area of ​​the surface is n. c 1.3×10 -7 mol / mm 2 The surface porosity is 0.5%, with pore diameters not exceeding 8 nm, and the surface contains amino groups. A biodegradable polymer layer partially covers the surface (covering 90% of the surface) and is bonded to the surface via hydrogen bonds. The biodegradable polymer layer is composed of sirolimus-polylactic acid and polylactic acid, with a total thickness of 12 μm. The polylactic acid has a number-average molecular weight of 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 6:16.

[0171] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0172] The nitrided iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the iron-based core was etched with argon ions at 25°C for 14 minutes. The average surface roughness Ra of the iron-based core was 8 nm.

[0173] A magnesium-cerium alloy layer was formed in the etched iron-based core using room-temperature magnetron sputtering. The parameters of the magnetron sputtering method were: ion source voltage of 2kV, bias voltage of 150V, temperature of 25℃, sputtering power of 5kW, and time of 120min.

[0174] The iron-based core with the magnesium-cerium alloy layer was treated with ammonia water with a concentration of 5 wt.% for 5 min to make the surface part have amino groups, thus obtaining a metal matrix;

[0175] A scaffold was prepared by spraying a 12 μm thick biodegradable polymer layer onto a portion of the surface of a metal substrate. The biodegradable polymer layer consisted of sirolimus-polylactic acid and polylactic acid, with the polylactic acid having a number-average molecular weight of 2 × 10⁻⁶.5 In the sirolimus-polylactic acid coating, the mass ratio of sirolimus to polylactic acid is 6:16.

[0176] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 16% was measured, and an OCT measurement showed a vascular stenosis rate of 15%. After 12 months, the stent weight loss rate was 62%.

[0177] Example 8

[0178] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0179] The metal matrix includes a nitrided iron-based core and a surface portion with a nitrogen content of 0.1 wt.% and a carbon content of no more than 2.11 wt.%.

[0180] The average surface roughness Ra of the iron-based core is 10 nm. The surface completely encapsulates the iron-based core surface, and the iron-based core and surface are bonded by metallic bonds. The interface is an iron-calcium-magnesium alloy layer, and the potential difference between the iron-based core and the surface is 2.0 V. The surface includes a calcium-magnesium alloy with a magnesium content of 30 wt.% and iron with a content of 0.02 wt.%. The corrosion potential Ec of the surface is -2.5 V, and the total molar amount n of each element per unit area of ​​the surface is... c 9.5×10 -8 mol / mm 2 The surface porosity is 0.6%, and the pore diameter is no greater than 15 nm. A biodegradable polymer layer partially covers the surface (95% coverage) and is bonded to the surface via hydrogen bonds. The biodegradable polymer layer is composed of sirolimus and polyethylene glycol, with a thickness of 20 μm. The number average molecular weight of the polyethylene glycol is 1.5 × 10⁻⁶. 5 The mass ratio of sirolimus to polyethylene glycol is 8:16.

[0181] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0182] The iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was simultaneously raised to 200°C. The iron-based core was then etched with argon ions for 6 minutes, resulting in an average surface roughness Ra of 10 nm for the iron-based core.

[0183] A calcium-magnesium alloy layer was formed on the surface of the etched iron-based core by magnetron sputtering. The parameters of the magnetron sputtering method were: ion source voltage of 1.0kV, bias voltage of 150V, heating temperature of 200℃, sputtering power of 5kW, and time of 100min.

[0184] The iron-based core with the calcium-magnesium alloy layer formed was heat-treated at 200°C for 10 minutes to obtain the metal matrix.

[0185] A 20 μm thick biodegradable polymer layer is sprayed onto the entire surface of the metal substrate.

[0186] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 8% was measured, and an OCT measurement showed a vascular stenosis rate of 15%. After 12 months, the stent weight loss rate was 45%.

[0187] Example 9

[0188] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0189] The metal matrix includes a nitrided iron-based core and a surface portion with a nitrogen content of 0.1 wt.% and a carbon content of no more than 2.11 wt.%.

[0190] The average surface roughness Ra of the iron-based core is 32 nm; the surface completely encapsulates the surface of the iron-based core, and the potential difference between the nitrided iron-based core and the surface is 0.15 V; the surface comprises an iron-rhenium alloy with an iron content of 33 wt.%, a corrosion potential Ec of -0.3 V, and the total molar amount n of each element per unit area of ​​the surface. c 2.7×10 -7 mol / mm 2 The porosity is 0.5%, and the pore diameter is no greater than 8 nm. The biodegradable polymer layer partially covers the surface portion (covering 95% of the surface) and is bonded to the surface portion by hydrogen bonds. The biodegradable polymer layer consists of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA, with a total thickness of 12 μm. The number-average molecular weight of the PLA is 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0191] The method for preparing an absorbable implantable stent in this embodiment includes the following steps:

[0192] The iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was simultaneously raised to 150°C. The iron-based core was then etched with argon ions for 60 minutes, resulting in an average surface roughness Ra of 32 nm for the iron-based core.

[0193] The etched iron-based core was electrodeposited to form an iron-rhenium alloy layer. The electrodeposition parameters were as follows: electrolyte composition: FeSO4·7H2O (0.15 mol / L), HO4Re (0.015 mol / L), citric acid (0.2 mol / L), pH 8.0, temperature 70℃, constant current electrodeposition, 316L stainless steel anode, and current density 0.02 A / cm². 2 Time: 0.3 hours.

[0194] A biodegradable polymer layer with a thickness of 8 μm was sprayed onto a portion of the iron-rhenium alloy layer. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid. The number average molecular weight of the polylactic acid was 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 13:16.

[0195] Three months after the stent was implanted in the canine coronary artery, the stent weight loss was 0%, and the vascular stenosis rate was 16% as measured by OCT. The stent weight loss rate was 50% after 12 months.

[0196] Example 10

[0197] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0198] The metal matrix includes a nitrided iron-based core and a surface portion with a nitrogen content of 0.1 wt.% and a carbon content of no more than 2.11 wt.%.

[0199] The iron-based core has an average surface roughness Ra of 3 nm, and the surface portion covers 85% of the iron-based core surface portion. The potential difference between the iron-based core and the surface portion is 0.2 V. The surface portion consists of an aluminum-copper-oxygen alloy layer with an aluminum content of 55 wt.% and an oxygen content of no more than 0.5 wt.%, and the surface portion does not contain iron. The corrosion potential Ec is -0.6 V, and the total molar amount n of each element per unit area of ​​the surface portion is... c It is 6.3*10 -10 mol / mm 2 The porosity is 0.05%, and the pore diameter is no greater than 2 nm. The biodegradable polymer layer completely covers the surface and is bonded to the surface by hydrogen bonds. The biodegradable polymer layer consists of three layers: polylactic-co-glycolic acid, sirolimus-polylactic-co-glycolic acid, and polylactic-co-glycolic acid, with a total thickness of 10 μm. The number-average molecular weight of polylactic-co-glycolic acid is 3 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid glycolic acid in the sirolimus-polylactic acid glycolic acid coating is 5:16.

[0200] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0201] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the iron-based core was etched with argon ions at 25°C for 6 minutes, so that the average surface roughness Ra of the iron-based core was 3nm.

[0202] An aluminum-copper-oxide alloy layer was formed on the etched iron-based core using room-temperature magnetron sputtering. The magnetron sputtering parameters were: ion source voltage of 0.8 kV, bias voltage of 200 V, temperature of 25 °C, sputtering power of 1 kW, and time of 10 min. A metal substrate was obtained.

[0203] A scaffold was prepared by spraying a 10 μm thick biodegradable polymer layer onto the entire surface of a metal substrate. The biodegradable polymer layer consisted of three layers: polylactic-co-glycolic acid (PLGA), sirolimus-PLGA, and PLA. The number-average molecular weight of the PLA was 3 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid glycolic acid in the sirolimus-polylactic acid glycolic acid coating is 5:16.

[0204] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 26% was measured, and an OCT measurement showed a vascular stenosis rate of 27%. After 12 months, the stent weight loss rate was 70%.

[0205] Example 11

[0206] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0207] The metal matrix includes a nitrided iron-based core and a surface portion with a nitrogen content of 0.1 wt.% and a carbon content of no more than 2.11 wt.%.

[0208] The iron-based core has an average surface roughness Ra of 4 nm. The surface completely encapsulates the iron-based core, and the core and surface are bonded by metallic bonds. The interface is an iron-aluminum-chromium-nitrogen alloy layer, and the potential difference between the core and surface is 0.3 V. The surface consists of an aluminum-chromium-nitrogen alloy layer with an aluminum content of 80 wt.% and a nitrogen content of no more than 0.5 wt.%, and also contains iron with a content of 0.03 wt.%. The corrosion potential Ec is -0.7 V, and the total molar amount n of each element per unit area of ​​the surface is... c 1.5×10 - 7 mol / mm 2 The porosity is 0.04%, and the pore diameter is no greater than 2 nm. The biodegradable polymer layer completely covers the surface and is bonded to the surface by hydrogen bonds. The biodegradable polymer layer consists of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with a total thickness of 14 μm. The number-average molecular weight of the polylactic acid is 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0209] The method for preparing the iron-based vascular stent in this embodiment includes the following steps:

[0210] The iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was simultaneously raised to 200°C. The iron-based core was then etched with argon ions for 8 minutes, resulting in an average surface roughness Ra of 4 nm for the iron-based core.

[0211] An aluminum-chromium-nitrogen alloy layer was formed on the etched iron-based core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 1.8 kV, bias voltage of 120 V, heating temperature of 200 °C, sputtering power of 1 kW, and time of 30 min.

[0212] A vascular stent was prepared by spraying a 14 μm thick biodegradable polymer layer onto the entire surface of the stent. The biodegradable polymer layer consisted of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA. The number-average molecular weight of the PLA was 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0213] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 15% was measured, and an OCT measurement showed a vascular stenosis rate of 12%. After 12 months, the stent weight loss rate was 60%.

[0214] Example 12

[0215] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0216] The metal matrix includes a nitrided iron-based core and a surface portion with a nitrogen content of 0.1 wt.% and a carbon content of no more than 2.11 wt.%.

[0217] The iron-based core has an average surface roughness Ra of 6 nm, and the surface completely encapsulates the iron-based core. The potential difference between the iron-based core and the surface is 0.4 V. The surface consists of an aluminum-chromium-nitrogen alloy layer with an aluminum content of 98 wt.% and an oxygen content of no more than 0.5 wt.%, and also contains iron with a content of 0.001 wt.%. The corrosion potential Ec is -0.8 V, and the total molar amount n of each element per unit area of ​​the surface is... c 3×10 -9 mol / mm 2 The porosity is 0.05%, and the pore diameter is no greater than 2 nm. The biodegradable polymer layer completely covers the surface and is bonded to the surface by hydrogen bonds. The biodegradable polymer layer consists of three layers: polyglycolic acid, sirolimus-polyglycolic acid, and polyglycolic acid, with a total thickness of 14 μm. The number average molecular weight of the polyglycolic acid is 3.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polyglycolic acid in the sirolimus-polyglycolic acid coating is 10:16.

[0218] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0219] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the temperature was raised to 200°C and the substrate was ion-etched for 12 minutes to make the average surface roughness Ra of the iron-based core 6nm.

[0220] An aluminum-chromium-oxide alloy layer was formed on the etched iron-based core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 2.5 kV, bias voltage of 100 V, heating temperature of 200 °C, sputtering power of 1 kW, and time of 40 min.

[0221] A vascular stent was prepared by spraying a 14 μm thick biodegradable polymer layer onto the entire surface of the stent. The biodegradable polymer layer consisted of three layers: polyglycolic acid, sirolimus-polyglycolic acid, and polyglycolic acid. The number average molecular weight of the polyglycolic acid was 3.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polyglycolic acid in the sirolimus-polyglycolic acid layer is 10:16.

[0222] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 22% was measured, and an OCT measurement showed a vascular stenosis rate of 12%. The stent weight loss rate after 12 months was 76%.

[0223] Example 13

[0224] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0225] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.05 wt.%, as well as a surface portion.

[0226] The iron-based core has an average surface roughness Ra of 10 nm; the surface completely encapsulates the iron-based core, and the iron-based core and surface are bonded by metallic bonds, with an interface of an iron-zinc alloy layer. The potential difference between the iron-based core and the surface is 0.15 V; the surface comprises an iron-zinc alloy with a zinc content of 6 wt.%, and a corrosion potential Ec of -0.6 V; the total molar amount n of each element per unit area of ​​the surface is... c It is 8.4×10 -9 mol / mm 2 The porosity is 1%, with pore diameters not exceeding 5 nm. The surface portion contains hydroxyl groups. A biodegradable polymer layer partially covers the surface portion and is bonded to it via hydrogen bonds. The biodegradable polymer layer is composed of sirolimus-polylactic acid, with a thickness of 15 μm. The number-average molecular weight of the polylactic acid is 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0227] The method for preparing the stent in this embodiment includes the following steps:

[0228] The iron-based core is placed into the vacuum chamber of the equipment, and the support is ion-etched at 100°C for 60 minutes to remove surface contaminants and oxide layers.

[0229] The surface of the etched iron-based core was subjected to ion implantation to form an iron-zinc alloy layer; the ion implantation parameters were: beam current 0.5mA, bias voltage -30kV, and implantation dose 4×10⁻⁶. 15 ions / cm 2 Processing time: 100 minutes;

[0230] After the treatment, the iron-based core containing the iron-zinc alloy layer was heat-treated at 400℃ for 30 minutes; the surface of the heat-treated iron-zinc alloy layer was treated with 2wt.% sodium hydroxide for 5 minutes to make the surface contain hydroxyl groups.

[0231] A 15μm thick biodegradable polymer layer was sprayed onto the surface of the treated magnesium-zinc alloy layer to prepare a vascular stent.

[0232] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 10% was measured, and an OCT measurement showed a luminal stenosis rate of 13%. The stent weight loss rate was 59% after 12 months.

[0233] Example 14

[0234] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0235] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.05 wt.%, as well as a surface portion.

[0236] The iron-based core has an average surface roughness Ra of 10 nm. The surface completely encapsulates the iron-based core, and the core and surface are bonded by metallic bonds. The interface is a zinc-iron alloy layer, and the potential difference between the core and surface is 0.12 V. The surface comprises a zinc-containing zinc alloy with a corrosion potential Ec of -0.56 V, and the total molar ratio of all elements per unit area of ​​the surface is 4.2 × 10⁻⁶. -9 mol / mm 2 The porosity is 0.5%, and the pore diameter is no greater than 10 nm. The surface contains hydroxyl groups. The biodegradable polymer layer completely covers the surface and is bonded to it by hydrogen bonds. The biodegradable polymer layer consists of two layers: sirolimus-polylactic acid and polylactic acid, with a total thickness of 16 μm. The weight-average molecular weight of the polylactic acid is 2 × 10⁻⁶. 5 The mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0237] The method for preparing the stent in this embodiment includes the following steps:

[0238] The iron-based core is placed into the vacuum chamber of the equipment at a temperature of 100°C, and the support is ion-etched for 60 minutes to remove surface contaminants and oxide layers.

[0239] The surface of the etched iron-based core was subjected to ion implantation to form an iron-zinc alloy layer; the ion implantation parameters were: beam current 0.5mA, bias voltage -30kV, and implantation dose 2×10⁻⁶. 15 ions / cm 2 Processing time: 60 minutes;

[0240] After the treatment, the iron-based core containing the iron-zinc alloy layer was heat-treated at 350℃ for 20 minutes; the surface of the heat-treated iron-zinc alloy layer was treated with 2wt% sodium hydroxide for 5 minutes to make the surface contain hydroxyl groups.

[0241] A 15μm thick biodegradable polymer layer was sprayed onto the surface of the treated magnesium-zinc alloy layer to prepare a vascular stent.

[0242] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 15% was measured, and an OCT measurement showed a vascular stenosis rate of 15%. After 12 months, the stent weight loss rate was 56%.

[0243] Example 15

[0244] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0245] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0246] The average surface roughness Ra of the iron-based core is 12 nm. The surface completely encapsulates the iron-based core surface, and the iron-based core and surface are bonded by metallic bonds. The interface is an iron-aluminum alloy layer, and the potential difference between the iron-based core and the surface is 1.2 V. The surface consists of pure aluminum and also contains iron, with an iron content of 0.001 wt.%. The corrosion potential Ec of the surface is -1.7 V. The total molar amount n of each element per unit area of ​​the surface is... c 1*10 -8 mol / mm 2 The surface porosity is 0.12%, and the pore diameter is no greater than 10 nm. A biodegradable polymer layer completely covers the surface; this layer consists of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA, with a total thickness of 10 μm. The number-average molecular weight of the PLA is 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0247] The method for preparing the iron-based vascular stent in this embodiment includes the following steps:

[0248] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the temperature was raised to 150°C and the substrate was ion-etched for 25 minutes, so that the average surface roughness Ra of the iron-based core was 12nm.

[0249] The etched iron-based core was then sputtered to form a pure aluminum layer. The parameters for the magnetron sputtering method were: ion source voltage of 2.0 kV, bias voltage of 100 V, heating temperature of 150 °C, sputtering power of 2 kW, and time of 80 min.

[0250] The iron-based core containing the aluminum layer was heat-treated at 230°C for 10 minutes.

[0251] A vascular stent was prepared by spraying a 10 μm thick biodegradable polymer layer onto the entire surface of the aluminum layer. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with the polylactic acid having a number-average molecular weight of 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0252] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 12% was measured, and an OCT measurement showed a vascular stenosis rate of 12%. The stent weight loss rate after 12 months was 58%.

[0253] Example 16

[0254] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0255] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0256] The average surface roughness Ra of the iron-based core is 12 nm. The surface completely encapsulates the iron-based core surface, and the iron-based core and surface are bonded by metallic bonds. The interface is an iron-aluminum alloy layer, and the potential difference between the iron-based core and the surface is 1.2 V. The surface consists of pure aluminum and also contains iron, with an iron content of 0.006 wt.%. The corrosion potential Ec of the surface is -1.7 V. The total molar amount n of each element per unit area of ​​the surface is... c 6*10 -8 mol / mm 2 The porosity is 0.8%, and the pore diameter is no greater than 10 nm. The biodegradable polymer layer completely covers the surface. The biodegradable polymer layer is composed of sirolimus-polylactic acid (PLA) and has a thickness of 10 μm. The number-average molecular weight of the PLA is 2.5 × 10⁻⁶. 5In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 11:16.

[0257] The method for preparing the iron-based vascular stent in this embodiment includes the following steps:

[0258] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the temperature was raised to 160°C and the substrate was ion-etched for 25 minutes, so that the average surface roughness Ra of the iron-based core was 12nm.

[0259] The etched iron-based core was then sputtered to form a pure aluminum layer. The parameters for the magnetron sputtering method were: ion source voltage of 2.0 kV, bias voltage of 100 V, heating temperature of 160 °C, sputtering power of 2 kW, and time of 80 min.

[0260] The iron-based core containing the aluminum layer was heat-treated at 230°C for 10 minutes.

[0261] A vascular stent was prepared by spraying a 10 μm thick biodegradable polymer layer onto the entire surface of the aluminum layer. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with the number average molecular weight of the polylactic acid being 2.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0262] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 10% was measured, and an OCT measurement showed a vascular stenosis rate of 12%. The stent weight loss rate was 58% after 12 months.

[0263] Example 17

[0264] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0265] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0266] The average surface roughness Ra of the iron-based core is 12 nm. The surface completely encapsulates the iron-based core surface, and the iron-based core and surface are bonded by metallic bonds. The interface is an iron-aluminum alloy layer, and the potential difference between the iron-based core and the surface is 1.2 V. The surface consists of pure aluminum and also contains iron, with an iron content of 0.01 wt.%. The corrosion potential Ec of the surface is -1.7 V. The total molar amount n of each element per unit area of ​​the surface is... c 9*10 -8 mol / mm 2The porosity is 0.05%, and the pore diameter is no greater than 10 nm. The biodegradable polymer layer completely covers the surface; the biodegradable polymer layer consists of two layers: polylactic acid (PLA) and sirolimus-PLA, with a thickness of 10 μm. The number-average molecular weight of the PLA is 3 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 9:16.

[0267] The method for preparing the iron-based vascular stent in this embodiment includes the following steps:

[0268] The iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was simultaneously raised to 170°C. The substrate was then ion-etched for 25 minutes to achieve an average surface roughness Ra of 12nm for the iron-based core.

[0269] The etched iron-based core was then sputtered to form a pure aluminum layer. The parameters for the magnetron sputtering method were: ion source voltage of 2.0 kV, bias voltage of 100 V, heating temperature of 170 °C, sputtering power of 2.2 kW, and time of 85 min.

[0270] The iron-based core containing the aluminum layer was heat-treated at 230°C for 15 minutes.

[0271] A vascular stent was prepared by spraying a 10 μm thick biodegradable polymer layer onto the entire surface of the aluminum layer. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with the polylactic acid having a number-average molecular weight of 3 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 9:16.

[0272] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 8% was measured, and an OCT measurement showed a vascular stenosis rate of 5%. After 12 months, the stent weight loss rate was 57%.

[0273] Example 18

[0274] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0275] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0276] The average surface roughness Ra of the iron-based core is 12 nm, and the potential difference between the iron-based core and the surface portion is 1.2 V. The surface portion includes pure aluminum and also contains iron at a content of 0.005 wt.%. The corrosion potential Ec of the surface portion is -1.7 V. The total molar amount n of each element per unit area of ​​the surface portion is... c 1.5×10 -7 mol / mm2 The surface porosity is 0.2%, and the pore diameter is no greater than 10 nm. A biodegradable polymer layer covers the entire surface. This biodegradable polymer layer is composed of sirolimus-polylactic acid (PLA) and has a thickness of 10 μm. The number-average molecular weight of the PLA is 3.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 9:16.

[0277] The method for preparing the nitrided iron-based vascular stent in this embodiment includes the following steps:

[0278] The nitrided iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was raised to 180°C and ion etched for 25 minutes, resulting in an average surface roughness Ra of 12 nm for the iron-based core.

[0279] A pure aluminum layer was formed on the surface of the etched iron-based core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 2.3 kV, magnetron bias of 50 V, heating temperature of 180 °C, sputtering power of 3 kW, and time of 90 min.

[0280] A vascular stent was prepared by spraying a 5 μm thick biodegradable polymer layer onto the entire surface of the treated pure aluminum layer. The biodegradable polymer layer consisted of sirolimus and polylactic acid, with the polylactic acid having a number average molecular weight of 3.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 9:16.

[0281] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 9% was measured, and an OCT measurement showed a vascular stenosis rate of 8%. After 12 months, the stent weight loss rate was 60%.

[0282] Example 19

[0283] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0284] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0285] The surface portion completely encapsulates the surface of the iron-based core, with a potential difference of 1.2V between the iron-based core and the surface portion. The surface portion comprises pure aluminum and also contains iron at a content of 0.008 wt.%. The corrosion potential Ec of the surface portion is -1.7V. The total molar amount n of each element per unit area of ​​the surface portion... c 2.1×10 -7 mol / mm 2The porosity is 0.2%, and the pore diameter is no greater than 25 nm. The biodegradable polymer layer completely covers the surface; the biodegradable polymer layer consists of two layers: sirolimus-polylactic acid and polylactic acid, with a total thickness of 10 μm. The number-average molecular weight of the polylactic acid is 4 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0286] The method for preparing the iron-based vascular stent in this embodiment includes the following steps:

[0287] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the temperature was raised to 230°C and the substrate was ion-etched for 25 minutes, so that the average surface roughness Ra of the iron-based core was 12nm.

[0288] The etched iron-based core was coated with pure aluminum by vapor deposition. The parameters of the vapor deposition method were: vapor deposition power 300W, time 240min, target distance 30cm, and argon protection heat treatment at 300℃ for 30min after vapor deposition.

[0289] A 10 μm thick biodegradable polymer layer was sprayed onto the entire surface of the pure aluminum layer. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid. The number average molecular weight of the polylactic acid was 4 × 10⁻⁶. 5 The mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0290] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 8% was measured, and an OCT measurement showed a vascular stenosis rate of 13%. After 12 months, the stent weight loss rate was 62%.

[0291] Example 20

[0292] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0293] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0294] The average surface roughness Ra of the iron-based core is 12 nm. The surface completely encapsulates the iron-based core surface, and the iron-based core and surface are bonded by metallic bonds. The interface is an iron-aluminum alloy layer, and the potential difference between the iron-based core and the surface is 1.2 V. The surface consists of pure aluminum and also contains iron, with an iron content of 0.05 wt.%. The corrosion potential Ec of the surface is -1.7 V. The total molar amount n of each element per unit area of ​​the surface is... c 1*10 -10 mol / mm 2The porosity is 0.2%, and the pore diameter is no greater than 25 nm. The biodegradable polymer layer covers the entire surface of the surface portion. The biodegradable polymer layer consists of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with a total thickness of 10 μm. Among them, the number average molecular weight of polylactic acid is 8 × 10⁻⁶. 4 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 7:16.

[0295] The method for preparing the nitrided iron-based vascular stent in this embodiment includes the following steps:

[0296] The nitrided iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was raised to 250°C and ion etched for 25 minutes, resulting in an average surface roughness Ra of 12 nm for the iron-based core.

[0297] A pure aluminum layer was formed on the surface of the etched iron-based core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 2.3 kV, magnetron bias of 50 V, heating temperature of 250 °C, sputtering power of 3 kW, and time of 85 min.

[0298] A vascular stent was prepared by spraying a 10 μm thick biodegradable polymer layer onto the entire surface of the treated pure aluminum layer. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid. The number average molecular weight of the polylactic acid was 8 × 10⁻⁶. 4 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 7:16.

[0299] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 16% was measured, and an OCT measurement showed a vascular stenosis rate of 18%. After 12 months, the stent weight loss rate was 54%.

[0300] Example 21

[0301] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0302] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0303] The average surface roughness Ra of the iron-based core is 12 nm. The surface completely encapsulates the iron-based core surface, and the iron-based core and surface are bonded by metallic bonds. The interface is an iron-aluminum alloy layer, and the potential difference between the iron-based core and the surface is 1.2 V. The surface includes an aluminum-manganese alloy with a manganese content of 1%, and also contains iron with a content of 0.01 wt.%. The corrosion potential Ec of the surface is -1.7 V. The total molar amount n of each element per unit area of ​​the surface is... c 3.5*10 -7mol / mm 2 The porosity is 0.2%, and the pore diameter is no greater than 25 nm; the biodegradable polymer layer covers the entire surface of the surface portion; the biodegradable polymer layer consists of two layers: sirolimus-polylactic acid and polylactic acid, with a total thickness of 10 μm, wherein the number average molecular weight of polylactic acid is 4.5 × 10⁻⁶. 5 In the paclitaxel-polylactic acid coating, the mass ratio of paclitaxel to polylactic acid is 10:6.

[0304] The method for preparing the nitrided iron-based vascular stent in this embodiment includes the following steps:

[0305] The nitrided iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was raised to 180°C and ion etched for 25 minutes, resulting in an average surface roughness Ra of 12 nm for the iron-based core.

[0306] A pure aluminum layer was formed on the surface of the etched iron-based core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 2kV, magnetron bias voltage of 50V, heating temperature of 180℃, sputtering power of 3kW, and time of 120min.

[0307] A 10 μm thick biodegradable polymer layer was sprayed onto the entire surface of the treated pure aluminum layer to prepare a vascular stent. The biodegradable polymer layer consisted of two layers: paclitaxel-polylactic acid and polylactic acid, both with a number-average molecular weight of 4.5 × 10⁻⁶. 5 In the paclitaxel-polylactic acid coating, the mass ratio of paclitaxel to polylactic acid is 10:16.

[0308] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 13% was measured, and an OCT measurement showed a vascular stenosis rate of 17%. After 12 months, the stent weight loss rate was 63%.

[0309] Example 22

[0310] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0311] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0312] The average surface roughness Ra of the iron-based core is 12 nm. The surface completely encapsulates the iron-based core surface, and the potential difference between the iron-based core and the surface is 1.2 V. The surface is pure aluminum and contains no iron. The corrosion potential Ec of the surface is -1.7 V. The total molar amount of each element per unit area of ​​the surface is nc = 1.5 × 10⁻⁶. -7 mol / mm 2The surface porosity is 0.8%, and the pore diameter is no greater than 10 nm. A biodegradable polymer layer completely covers the surface; this layer consists of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA, with a total thickness of 10 μm. The number-average molecular weight of the PLA is 3.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 5:16.

[0313] The method for preparing the stent in this embodiment includes the following steps:

[0314] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the support was etched with argon ions at 25°C for 25 minutes, so that the average surface roughness Ra of the iron-based core was 12 nm.

[0315] The etched iron-based core was then used to form a pure aluminum layer by room-temperature magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 2.3kV, bias voltage of 50V, temperature of 25℃, sputtering power of 3kW, and time of 100min.

[0316] A scaffold was prepared by spraying a 10 μm thick biodegradable polymer layer onto the entire surface of the aluminum layer. The biodegradable polymer layer consisted of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA. The number-average molecular weight of the PLA was 3.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 5:16.

[0317] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 12% was measured, and an OCT measurement showed a vascular stenosis rate of 10%. After 12 months, the stent weight loss rate was 65%.

[0318] Example 23

[0319] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0320] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0321] The average surface roughness Ra of the iron-based core is 12 nm. The surface completely encapsulates the iron-based core surface, and the potential difference between the iron-based core and the surface is 1.2 V. The surface is pure aluminum and contains no iron. The corrosion potential Ec of the surface is -1.7 V. The total molar amount n of each element per unit area of ​​the surface is... c 3*10 -7 mol / mm 2The surface porosity is 0.2%, and the pore diameter is no greater than 25 nm. The biodegradable polymer layer completely covers the surface and is bonded to it by hydrogen bonds. The biodegradable polymer layer consists of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with a total thickness of 10 μm. The number-average molecular weight of the polylactic acid is 4 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0322] The preparation method of the stent in this comparative example includes the following steps:

[0323] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the support was ion-etched at 25°C for 25 minutes to make the average surface roughness Ra of the iron-based core 12nm.

[0324] The etched iron-based core was then used to form a pure aluminum layer using a room-temperature magnetron sputtering method. The parameters for the magnetron sputtering method were: ion source voltage of 2.3kV, bias voltage of 50V, temperature of 25℃, sputtering power of 3kW, and time of 130min.

[0325] A scaffold was prepared by spraying a 10 μm thick biodegradable polymer layer onto the entire surface of the aluminum layer. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with the polylactic acid having a number-average molecular weight of 2 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0326] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 10% was measured, and an OCT measurement showed a vascular stenosis rate of 15%. After 12 months, the stent weight loss rate was 65%.

[0327] Comparative Example 1

[0328] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0329] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0330] The average surface roughness Ra of the nitrided iron-based core is 12 nm; the potential difference between the iron-based core and the surface is 1.2 V; the surface includes pure aluminum and also contains iron at a content of 0.001 wt.%; the corrosion potential Ec of the surface is -1.7 V; and the total molar amount n of each element per unit area of ​​the surface is... c 1×10 -11 mol / mm 2The surface porosity is 1.5%, and the pore diameter is no greater than 25 nm. A biodegradable polymer layer completely covers the surface. This biodegradable polymer layer is composed of sirolimus-polylactic acid (PLA) and has a thickness of 10 μm. The number-average molecular weight of the PLA is 3.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 9:16.

[0331] The method for preparing the absorbable implantable stent in this comparative example includes the following steps:

[0332] The nitrided iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was raised to 200°C and ion etched for 25 minutes, resulting in an average surface roughness Ra of 12 nm for the iron-based core.

[0333] A pure aluminum layer was formed on the surface of the etched iron-based core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 2.0 kV, bias voltage of 50 V, heating temperature of 200 °C, sputtering power of 1 kW, and time of 10 min.

[0334] A 10 μm thick biodegradable polymer layer was sprayed onto the surface of the treated pure aluminum layer to prepare a scaffold. The biodegradable polymer layer was composed of sirolimus and polylactic acid, with the polylactic acid having a number-average molecular weight of 3.5 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 9:16.

[0335] Three months after the stent was implanted in the dog's coronary artery, a 55% weight loss was measured, and an OCT measurement showed a vascular stenosis rate of 85%.

[0336] Comparative Example 2

[0337] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0338] The metal matrix includes a nitrided iron-based core with a carbon content of no more than 2.11 wt.% and a nitrogen content of 0.1 wt.%, as well as a surface portion.

[0339] The surface portion completely encapsulates the surface of the iron-based core, and the iron-based core and surface portion are bonded by metallic bonds. Their interface is an iron-aluminum alloy layer, and the potential difference between the iron-based core and the surface portion is 1.2V. The surface portion consists of pure aluminum and also contains iron, with an iron content of 0.009 wt.%. The corrosion potential Ec of the surface portion is -1.7V. The total molar amount n of each element per unit area of ​​the surface portion... c 2.5×10 -6 mol / mm 2The porosity is 0.5%, and the pore diameter is no greater than 10 nm. The biodegradable polymer layer completely covers the surface and consists of three layers: polylactic acid (PLA), sirolimus-PLA, and PLA. The total thickness of the biodegradable polymer layer is 8 μm, and the number-average molecular weight of the PLA is 1 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0340] The preparation method of the stent in this comparative example includes the following steps:

[0341] The iron-based core was installed in the vacuum chamber of the equipment. After evacuation, the temperature was raised to 200°C and the substrate was ion-etched for 25 minutes, so that the average surface roughness Ra of the iron-based core was 12nm.

[0342] The etched iron-based core was then sputtered to form a pure aluminum layer. The parameters for the magnetron sputtering method were: bias voltage of 150V, heating temperature of 200℃, sputtering power of 5kW, and time of 120min.

[0343] A vascular stent was prepared by spraying an 8 μm thick biodegradable polymer layer onto the entire surface of the aluminum layer. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with the number-average molecular weight of the polylactic acid being 1 × 10⁻⁶. 5 In the Da, the mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 10:16.

[0344] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 5% was measured, and an OCT measurement showed a vascular stenosis rate of 23%. The stent weight loss rate was 28% after 12 months.

[0345] Comparative Example 3

[0346] An absorbable implantable stent includes a metal matrix and a biodegradable polymer layer on the surface of the metal matrix.

[0347] The iron-based core is nitrided iron with a nitrogen content of 0.04 wt.% and a carbon content not exceeding 2.11 wt.%. The average surface roughness Ra of the iron-based core is 5 nm. The surface completely encapsulates the surface of the iron-based core, and the iron-based core and the surface are bonded by metallic bonds. The interface is an iron-manganese-copper-carbon alloy layer, and the potential difference between the iron-based core and the surface is 0.1 V. The surface contains manganese with a manganese content of 15 wt.% and a carbon content not exceeding 0.5 wt.%, and also contains iron with a content of 0.01 wt%. The metal corrosion potential Ec of the surface is -0.3 V. The total molar amount n of each element per unit area of ​​the surface is... c 4.5×10 -8 mol / mm 2The porosity is 5%, and the pore diameter is no greater than 950 nm. The surface contains amino groups. The biodegradable polymer layer partially covers the surface (covering 95% of the surface) and is bonded to the surface by hydrogen bonds. The biodegradable polymer layer consists of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid, with a total thickness of 10 μm. The number average molecular weight of the polylactic acid is 2 × 10⁻⁶. 5 In the sirolimus-polylactic acid coating, the mass ratio of sirolimus to polylactic acid is 12:16.

[0348] The method for preparing the absorbable implantable stent in this embodiment includes the following steps:

[0349] The iron-based core was placed into the vacuum chamber of the equipment, and after evacuation, the temperature was simultaneously raised to 300°C. The iron-based core was etched with argon ions for 10 minutes, and the average surface roughness Ra of the iron-based core was 5 nm.

[0350] A manganese-copper-carbon alloy layer was formed on the surface of the etched iron-based core using magnetron sputtering. The parameters for magnetron sputtering were: ion source voltage of 0.6 kV, bias voltage of 450 V, heating temperature of 300 °C, sputtering power of 3.5 kW, and time of 100 min.

[0351] The iron-based core containing the manganese-copper-carbon alloy layer was heat-treated at 400℃ for 30 min; the surface of the heat-treated manganese-copper-carbon alloy layer was treated with 15wt.% ammonia water for 20 min.

[0352] A scaffold was prepared by spraying a 10 μm thick biodegradable polymer layer onto its surface. The biodegradable polymer layer consisted of three layers: polylactic acid, sirolimus-polylactic acid, and polylactic acid. The number average molecular weight of the polylactic acid was 2 × 10⁻⁶. 5 The mass ratio of sirolimus to polylactic acid in the sirolimus-polylactic acid coating is 12:16.

[0353] Three months after the stent was implanted in the canine coronary artery, a stent weight loss of 30% was measured, and an OCT measurement showed a vascular stenosis rate of 42%. After 12 months, the stent weight loss rate was 88%.

[0354] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0355] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. A metal matrix for absorbable medical devices, characterized by, It includes the core and the surface.

2. The metallic matrix for absorbable medical devices according to claim 1, wherein The number of metal elements in the core is no more than the number of metal elements in the surface portion; the surface portion contains at least one metal element A that is the same as that in the core portion; the surface portion comprises at least one elemental metal and / or metal alloy formed by at least one metal element B selected from iron, magnesium, aluminum, calcium, sodium, copper, manganese, chromium, selenium, molybdenum, cobalt, nickel, vanadium, tin, strontium, cerium, lithium, potassium, palladium, tungsten, titanium, rhenium, gold, platinum, tantalum, germanium, bismuth, silver, gallium, niobium, hafnium, zinc and zirconium.

3. The metallic matrix for absorbable medical devices according to claim 1, wherein There is an interface between the surface portion and the core portion; the surface portion wraps around the core portion along the interface; the surface portion includes 0.0001 wt.% to 5 wt.% of non-metallic elements; the non-metallic elements include at least one of carbon, nitrogen, oxygen, boron, sulfur, phosphorus, hydrogen, and silicon; the surface portion does not contain zinc or the zinc content in the surface portion is 0.0001 wt.% to 6 wt.%.

4. The metallic matrix for absorbable medical devices according to claim 2, wherein The content of the at least one metal element A, which is the same as the core, in the surface portion is 0.0001 wt.% to 6 wt.% or 30 wt.% to 99 wt.% of the total mass of the surface portion; the content of the at least one metal element A, which is the same as the core, in the surface portion increases from the outer edge of the surface portion to the interface, or the at least one metal element A exists only in the portion of the surface portion near the core; the content of the at least one metal element A at the outer edge of the surface portion is 0 or tends to be 0; the content of the at least one metal element B decreases from the outer edge of the surface portion to the interface.

5. The metallic matrix for absorbable medical devices according to claim 1, wherein The porosity of the surface portion is no greater than 3%; the pore diameter of the surface portion is no greater than 1000 nm. The metal element A is at least one selected from iron, magnesium, zinc, manganese, and aluminum; the iron content in the core is greater than 25 wt.%; the core includes 200 ppm to 2000 ppm of nitrogen; the carbon content in the core is less than or equal to 2.11 wt.%; the surface portion contains iron, and the iron content is 0.0001 wt.% to 3 wt.% or 30 wt.% to 99 wt.% of the total mass of the surface portion.

6. The metallic matrix for absorbable medical devices according to claim 1, wherein The metal corrosion potential E of the surface portion c The value is -0.15V to -2.9V, or the metal corrosion potential E of the surface portion. c The absolute value of the potential / potential difference between the core and the surface is [-0.15V, -0.74V] or [-0.77V, -2.9V]; or the absolute value of the potential / potential difference between the core and the surface is [0.05V, 0.20V] or [0.23V, 2.5V].

7. The metallic matrix for absorbable medical devices according to claim 1, wherein The total molar amount n of each element per unit area of ​​the surface portion c 1.00×10 -10 mol / mm 2 ~1×10 -6 mol / mm 2 The total molar amount n of each element per unit area of ​​the surface portion c 1.00×10 -10 mol / mm 2 ~5.00×10 -7 mol / mm 2 The total molar amount n of each element per unit area of ​​the surface portion c 1.00×10 -10 mol / mm 2 ~1.50×10 -7 mol / mm 2 The surface portion and the core portion are connected by metallic bonds and / or ionic bonds.

8. The metallic matrix for absorbable medical devices according to claim 1, wherein The surface portion contains at least one of calcium, magnesium, iron, aluminum or manganese, and its content is 30 wt.% to 100 wt.% of the total mass of the surface portion; the average roughness Ra of the outer edge of the core portion is 3 nm to 40 nm.

9. An absorbable medical device, characterized in that, It includes the metal substrate as described in any one of claims 1 to 8 and a biodegradable polymer layer covering at least a portion of the surface of the metal substrate.

10. The absorbable medical device according to claim 9, characterized in that, The metal corrosion potential E of the metal base surface portion c The total molar amount n of each element per unit area of the surface portion c The number average molecular weight M of the degradable polymer in the degradable polymer layer p The size satisfies the following relationship: where E c has units of V, n c has units of mol / mm 2 , M p has units of Da.

11. Absorbable medical device according to claim 9 or 10, characterized in that The surface portion further includes a chemical modification layer attached to its surface; the chemical modification layer includes at least one of the following functional groups: hydroxyl, ether bond, aldehyde group, carbonyl group, carboxyl group, ester group, amide group, amino group, nitro group, sulfonic acid group, mercapto group, olefin double bond, alkyne triple bond, halogen atom or azo functional group.

12. The absorbable medical device of claim 9 or 10, wherein, The total thickness of the degradable polymer layer is 5-30 μm; the degradable polymer layer comprises a degradable polymer, the number average molecular weight of the degradable polymer is 5 x 10 3 Da-1 x 10 6 Da; the pKa of the degradable polymer is 3.0-8.

0.

13. The absorbable medical device of claim 9 or 10, wherein, The degradable polymer includes at least one of degradable polyester, degradable polyanhydride, degradable polyamino acid, or a binary or multi-component degradable copolymer formed by copolymerizing the monomers corresponding to degradable polyester, degradable polyanhydride, and degradable polyamino acid.

14. The absorbable medical device according to claim 13, wherein, The biodegradable polyester includes at least one of polylactic acid, polyglycolic acid, polylactic-glycolic acid copolymer, lactide-caprolactone copolymer, polylactic-glycolic acid, polycaprolactone, polyhydroxy fatty acid ester, polyacrylate, polysuccinate, polysalicylic anhydride ester, polytrimethylene carbonate, polydioxane, poly(β-alkanoate), poly(β-hydroxybutyrate), polyethylene glycol ester, polyethylene adipate, or polyhydroxybutyrate valerate. The biodegradable polyanhydride includes at least one of poly(1,3-bis(p-carboxyphenoxy)propane-sebacic acid, polyurethane dimer-sebacic acid, or polyfumaric acid-sebacic acid. The biodegradable polyamino acids include at least one of polyglycine, polyalanine, polyvaline, polyleucine, polyisoleucine, polymethionine, polyproline, polytryptophan, polyserine, polytyrosine, polycysteine, polyphenylalanine, polyasparagine, polyglutamine, polythreonine, polyarginine, polyhistidine, polyselenocysteine, polypyrrolidone, polyglutamic acid, polyaspartic acid, polyornithine, polylysine, and their derivatives.

15. The absorbable medical device of claim 9 or 10, wherein, The biodegradable polymer layer includes an active pharmaceutical ingredient; the active pharmaceutical ingredient includes at least one of the following: an anti-angiogenic drug, an antiplatelet drug, an antithrombotic drug, an anti-inflammatory drug, or an anti-sensitizing drug. The anti-angiogenic drugs include at least one of paclitaxel, rapamycin and its derivatives; the antiplatelet drugs include at least one of cilostazol, aspirin, clopidogrel, ticagrelor, tirofiban or dipyridamole; the antithrombotic drugs include at least one of heparin, low molecular weight heparin, fondaparinux sodium or argatroban. The anti-inflammatory drugs include at least one of dexamethasone, prednisone, ibuprofen, methotrexate, or levofloxacin; the anti-sensitizing drugs include at least one of calcium gluconate, loratadine, fexofenadine, ebastine, mizolastine, chlorpheniramine, diphenhydramine, triamcinolone, promethazine, levocetirizine, cortisone, hydrocortisone, or methylprednisolone.

16. The absorbable medical device of claim 9 or 10, wherein, The implantable medical devices include luminal stents, occluders, gaskets, artificial blood vessels, vascular clips, sutures, dental implants, orthopedic implants, gynecological implants, andrological implants, or respiratory implants. The luminal stents include vascular stents, airway stents, esophageal stents, biliary stents, intestinal stents, urethral stents, nerve stents, or pancreatic stents. The vascular stents include heart valve stents, coronary stents, pulmonary artery stents, renal artery stents, vertebral artery stents, covered stents, or peripheral stents. The orthopedic implants include bone screws, bone plates, joints, rivets, anchors, bolts, intramedullary nails, or interbody fusion devices.

17. A method of making an absorbable medical device, comprising: include: 1) A surface portion is formed on the core surface to form a metal substrate for a medical device; 2) A biodegradable polymer layer is formed on the surface of the metal substrate.

18. The method of claim 17, wherein the absorbable medical device is formed by: The surface portion in step 1) is formed by at least one of ion implantation, physical vapor deposition, or electrodeposition; prior to step 1), an ion etching step is also included; The ion etching is performed in a vacuum environment at 25°C to 420°C using Ar + The ion etching is performed for 5 minutes to 100 minutes.

19. The method for preparing the absorbable medical device according to claim 18, characterized in that, The ion implantation beam current is 0.1-10 mA, the bias voltage is 10-90 kV, the implantation dose is 1×10 11 ~9×10 16 ions / cm 2 , and the time is 20-120 min. The physical vapor deposition method includes magnetron sputtering or vacuum evaporation. The magnetron sputtering ion source voltage is 0.5kV to 3.0kV, the bias voltage is 5V to 600V, the heating temperature is 25℃ to 420℃, the sputtering power is 1.0kV to 10kW, and the time is 20min to 240min; the gaseous ions include argon ions; The vacuum evaporation method uses a power of 0.2kV to 5kW, a target distance of 15cm to 45cm, and a time of 40min to 360min. The electrodeposition includes constant voltage electrodeposition, constant current electrodeposition, or pulsed electrodeposition. The constant voltage electrodeposition uses a voltage of 2V to 50V, and the constant current electrodeposition uses a current density of 0.01A / cm². 2 ~3.0A / cm 2 The current density for pulse electrodeposition is 0.01 A / cm. 2 ~3.0A / cm 2 The electrodeposition temperature is 10–80°C, and the pH value of the electrodeposition electrolyte is 2.0–9.

0.

20. The method for preparing the absorbable medical device according to claim 17, characterized in that, Before step 2), the metal substrate is subjected to heat treatment and / or surface modification; the heat treatment is carried out under an inert gas atmosphere at a temperature of 100°C to 420°C for a time of 10 min to 60 min. The surface modification involves acidifying, alkalizing, or salinizing the metal substrate to form the chemical modification layer on the outer edge of the surface. The concentration of acid used in the acidification treatment is 0.5 wt.% to 5 wt.%, and the treatment time is 10 s to 5 min; The concentration of alkali used in the alkalization treatment is 2 wt.% to 10 wt.%, and the treatment time is 0.5 min to 5 min; The salt concentration used in the salinization treatment is 5 wt.% to 20 wt.%, and the treatment time is 1 min to 10 min.